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Pro-inflammatory cytokine interleukin (IL)-18 and novel T helper cell type 2 
(Th2) cytokine IL-25 have been shown to be elevated in allergic airway inflammation. 
We investigated the intracellular mechanisms regulating the lL-18- and IL-25-induced 
Thl /2 cytokines and chemokines from human T helper (Th) lymphocytes upon 
costimulation by anti-CD3 and anti-CD28 antibodies and the underlying molecular 
mechanisms, as well as the surface expression of adhesion molecules, chemokine 
receptors and costimulatory molecules. 
To generate a profile of cytokines and chemokines, the expression of Thl 
cytokines tumor necrosis factor (TNF)-a, interferon (IFN)-Y, Th2 cytokines IL-5, IL-6, 
IL-IO, and chemokines interferon-y inducible protein (IP)-10，monokine induced by 
interferon-y (MIG), regulated upon activation normal T cell expressed and secreted 
(RANTES), macrophage inflammatory protein (MlP)-la and IL-8 were assayed by 
bead-based cytokine array using flow cytometry or ELISA. 
We found that IL-18 could synergistically induce the release of the above Thl/2 
cytokines and chemokines from anti-CD3 and anti-CD28 antibodies costimulated Th 
cells, whereas IL-25 could only induce the release of Th2 cytokines IL-5, lL-6 and 
IL-10 and chemokines IP-10, MIG and RANTES. 
In an attempt to elucidate the intracellular mechanisms regulating the induction 
of cytokines and chemokines, nuclear factor-KB (NF-KB) and phosphorylated p38 
mitogen-activated protein kinase (p38 MAPK), phosphorylated c-Jun NH2-terminaI 
kinase (JNK) and phosphorylated extracellular signal-regulated kinase (ERK) were 
assessed by electrophoretic mobility shift assay or Western blot. BAY 11-7082, 
SB203580, SP600125 and PD098059, the selective inhibitors of NF-KB，p38 MAPK, 
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JNK and ERK pathways respectively, were used to confirm the regulatory 
mechanisms. 
Results show that in costimulated Th cells, IL-18 induced IFN-y, TNF-a, lL-5, 
IL-6 and IL-10, and IL-25 induced IL-5 and lL-10 were mediated by the activation of 
p38 M A R K , E R K and NF-KB but not JNK, while IL-25-induced IL-6 was mediated 
by ERK and N F - K B only. Regarding chemokine release, IL-18 and IL-25-induced 
release of IP-10, MIG and RANTES were mediated by JNK only, while 
IL-18-induced MlP- la and IL-8 was mediated by NF-KB, and both ERK and p38 
MARK, respectively. Moreover, we found that the underlying mechanism for IL-18 
and IL-25 induced effects was due to the upregulation of IL-18 and IL-25 receptors 
upon costimulation. The induced IL-18 receptor but not IL-25 receptor was found to 
be mediated by the activation of ERK, p38 MAPK and NF-KB. Therefore, 
IL-18-induced cytokines and chemokines are mainly regulated by costimulation 
activated MAPKs and NF-KB and the subsequent upregulation of I L - 1 8 receptor. 
However, IL-25-induced cytokines and chemokines were regulated by costimulation 
mediated upregulation of IL-25 receptor and the IL-25 activated intracellular MAPKs 
a n d NF-KB. 
To facilitate our understanding of the activation and recruitment of Th cells and 
their interaction with other immune cells, we investigated the Th cell surface 
expression of adhesion molecules like leukocyte function-associated antigen (LFA)-l 
and intracellular cell adhesion molecule (ICAM)-I, cytokine and chemokine receptors 
like IL-2R, CCR5, CXCR3 and costimulatory molecules like inducible costimulator 
(ICOS) and cytotoxic T lymphocyte associated antigen (CTLA)-4. The above surface 
ligands except CCR5 were found to be upregulated upon costimulation, however, the 
induced expression could not be further enhanced by IL-18 and IL-25. 
The present study shows that IL-18 and IL-25 together with costimulation can 
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worsen airway inflammation and hyperresponsiveness by production of both Thl/2 
cytokines and chemokines upon airway infection. In view of recent advances in the 
application of M A P K and N F - K B inhibitors as potential anti-inflammatory agents in 
asthma, our study of differential mechanisms on the activation of Th cells should 
provide new insights on the development of therapeutic intervention for inflammatory 
diseases, particularly in severe asthma that usually contains both the activation of Thl 





近年硏究顯示，致發炎細胞因子中的白介素-18 ( IL -18 )和新發現的第 
二類型輔助性T淋巴細胞（Th2)之細胞因子中的白介素-25 (IL-25)的表達水 
平在過敏性呼吸道炎症中都顯著提升，因此在本硏究中，我們著重探討在抗白 
細胞分化抗原3 (CD 3)抗體和抗白細胞分化抗原28 (CD 28)抗體的共同激發 
下，輔助性T淋巴細胞（Th)被IL-18和IL-25刺激後,釋放出第一類型及第二 
類型輔助性T淋巴細胞（Thl/2)之細胞因子和趨化因子及其細胞內信號傳導和 
分子機制。我們亦會探討黏附分子（ a d h e s i o n m o l e c u l e s ) ,趨化因子 
(chemokines)受體和共同激發分子（costimulatory molecu le s )在細胞表面 
上的表達狀況。 
我們首先利用流式蛋白分析系統（cytometric beads ar ray , CBA)及酵 
素連結免疫吸附分析法（ELISA)來量度及比較Thl細胞因子中的腫瘤壞死因子 
(tumor necrosis f a c to r , T N F ) - A、干擾素（ i n t e r f e r o n , IFN)-Y, Th2 細 
胞因子中的白介素 - 5 �白介素 - 6 �白介素 - 1 0和趨化因子中的Y干擾素誘生蛋 
白（ interferon-Y- inducible pro te in , I P - 1 0 ) � 干擾素 R 誘生的單核因子 
(MIG)、調節活化的正常T細胞表達和分泌的因子（RANTES)、巨職細胞炎症 
蛋白 - l a (MlP- la)及白介素 -8的表達水平。 
實驗結果顯示，經 I L - 1 8 � C D 3抗體和CD 2 8抗體的共同刺激後 J h細 
胞會釋放出更多以上所提及過的Thl /2細胞因子及趨化因子，但經 IL-25�CD 
3抗體和CD 28抗體的共同刺激後，輔助性T淋巴細胞只會釋放出更多Th2細 





我們通過凝膠阻滯電泳（凝膠電泳遷移率）（electrophoretic mobili ty s h i f t 
assay)來檢測細胞內信號傳導機制中的核因子（nuclear f a c t o r , NF)-KB,力口 
上採用蛋白質印跡分析（Western blot)來檢測憐酸化p38絲裂原活化蛋白激酶 
(mitogen-act ivated protein kinase, MAPK)的變化，憐酸化 d u n 氣基末端 
激酶（ c - I u n NH2-terminal kinase, � N K ) 和憐酸化细胞外信號調節激酶 
( e x t r a c e l l u l a r s ignal - regula ted kinase, ERK)的變化。除此之外，本硏 
究亦運用信號傳導機制中酶的選擇性抑制劑：抑制NF-KB的BAY11-7082� 
抑制 p38 MAPK 的 S B 2 0 3 5 8 0 �抑制 JNK 的 SP600125 和抑制 ERK 的 PD98059 ’ 
來進一步確認IL-18和IL-25調控Th細胞的信號傳導途徑。 
硏究結果發現，經 I L - 1 8誘發出來的 I F N - Y � T N F - o c � I L - 5 � I L - 6和 
I L - 1 0 ,及經 I L - 2 5誘發出來的 I L - 5和 I L - 1 0是由激活p 3 8 MAPK�ERK和NF-
KB信號途徑而成，但並非由激活 INK信號途徑而成。而經 IL-25誘發出來的 
IL - 6就是通過激活ERK和NF-KB信號途徑而成。在趨化因子方面，經 IL-18 
和IL-25誘發出來的IP-10�MIG和RANTES就只有通過激活INK信號途徑而成， 
但從 I L - 1 8誘發出來的M l P - l a和 I L - 8就是分別通過激活N F - K B信號途徑以 








過CD 3和CD 28抗體的共同刺激下，弓丨發IL-25受體水平上升，加上IL-25本 
身的刺激令各種MAPKs和NF-KB信號途徑被激活而成。 
爲了更清楚了解Th細胞的被激活性、募集性及與其他免疫細胞的互相作 
用，我們檢測了黏附分子中的白細胞功能相關抗原（ l e u k o c y t e funct ion-
assoc ia ted ant igen, LFA)-1 和細胞間黏附分子（ i n t e rce l lu la r adhesion 
molecule, I C A M ) - 1 ;細胞因子及趨化因子受體中的 I L - 2受體（ I L - 2 R ) � C C 
趨化因子受體5 (CCR5)�CXC趨化因子受體3 (CXCR3);以及共同激發分子中 
的誘導性共刺激分子（inducible cost imulator, I C O S )和血細胞毒性T淋巴 
細胞相關分子4 (CTLA-4),在Th細胞表面上的表達狀況。結果顯示，在CD 3 
和CD 28抗體的共同刺激下，除了 CCR5外，其餘所有細胞表面上配體的表達水 
平都顯著上升。但是其表達水平並不會被 I L - 1 8和 I L - 2 5的刺激而繼續增 
加 ° 
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Chapter 1 Introduction 
Chapter 1 
Introduction 
1.1 Human Th lymphocytes and their immunopathogenic roles 
1.1.1 Characteristics of Th lymphocytes 
T helper (Th) cells are a sub-group of T lymphocytes involved in activating and 
directing other immune cells such as B cells, macrophages, eosinophils and mast cells. 
Derived from the thymus, Th cells are characterized by their small size (about 7 |im in 
diameter), high nucleus/cytoplasm ratio and few cytoplasmic organelles [Zak et al, 
1985]. Besides, mature Th cells are known to express the surface protein CD4, which 
distinguishes them from other T cell subsets like cytotoxic T lymphocytes (CTL) and 
suppressor T lymphocytes, etc. 
1.1.2 Migration and activation 
Following T cell development, naive Th cells leave the thymus and spread 
throughout the body, including lymph nodes. Th cells express the CD3/T cell receptor 
(TCR) complex which interacts with class II major histocompatibility complex (MHC) 
molecules exclusively found on the surface of professional antigen presenting cells 
(APCs), such as macrophages and dendritic cells (DCs). 
During infection, APCs travel from the site of infection to the lymph nodes and 
present the processed antigen peptides to naive Th cells. This constitutes the primary 
signal. However, interactions between costimulatory molecules such as CD28 on Th 
1 
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cells and B7-1 (CD80) or B7-2 (CD86) ligands on APCs are essential for optimal 
activation [Damle et al, 1988]. Lack of costimulatory signal can drive Th cells to enter 
a state of anergy or undergo apoptosis. Instead, the CD28-mediated signal augments 
the proliferation and secretion of multiple cytokines such as interferon (IFN)-'y, 
interleukin (IL)-2 and IL-4 [Tokoyoda et al, 2004]. 
1.1.3 Th cell differentiation 
The differentiation of Th subsets into Thl and Th2 cells was first documented in 
murine Th cells secreting cytokines of two different patterns [Mosmann et al, 1986]. 
In short, IFN-y secreted from Thl cells can induce differentiation of Th cells into Thl 
cells and inhibit the proliferation of Th2 cells [Szabo et al, 2000], while IL-4 and 
IL-10 secreted from Th2 cells can induce the polarization of Th2 cells and inhibit the 
function of Thl cells [Fiorentino et al, 1989; Swain et al, 1990]. It is now known that 
T-box expressed in T cells (T-bet) and GATA-binding protein (GATA)-3 are the 
typical transcription factors for Thl and Th2 cells respectively [Szabo et al, 2000; 
Zheng and Flavell, 1997]. 
The Thl/2 classification scheme has been used to relate overall cytokine 
production patterns to clinical outcomes in a variety of pathological states [Abbas et 
al, 1996]. For example, allergen-reactive Th2 cells are primarily involved in 
Immunoglobulin (Ig)E-mediated allergic diseases, such as allergic rhinitis, asthma, 
eczema and urticaria [Roitt et al, 1998], while the expression of delayed type 
hypersensitivity (DTH), such as Mycobacterium tuberculosis infection is 
characterized by Thl cells [Osio et al, 2005]. 
2 
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Figure 1.1 Th cell activation and differentiation 
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1.1.4 Pathological roles 
The involvement of Th cells in hypersensitivity response has been well studied. 
Type 1 hypersensitivity responses, such as atopic rhinitis, bronchial asthma, and 
urticaria, are mediated by IgE antibodies which lead to the release of histamines and 
leukotrienes from mast cells [Pawankar et al, 2003]. Th cells are important for the 
regulation of IgE synthesis in two ways, by releasing Th2 cytokines IL-4, IL-13 and 
interacting with the B cell surface antigen CD40 and its ligand CD40L [Bacharier et 
al, 2000]. On the other hand, the expression of DTH is highly dependent on Thl cells 
[Osio et al, 2005]. During the process, Thl cells generate cell-mediated immune 
response by producing IL-2 and IFN-y, leading to the activation of CTLs and 
macrophages. Besides, Th cells are central in autoimmune diseases, such as 
rheumatoid arthritis (RA), insulin-dependent diabetes mellitus (IDDM) and multiple 
sclerosis (MS), which are chronic inflammatory and autoimmune diseases 
characterized by Thl cell response [Parkin and Cohen, 2001]. 
Among the diseases, we are particularly interested in bronchial asthma, which is 
characterized by airway hyperresponsiveness (AHR), eosinophilic airway 
inflammation, airway remodeling, mucus hypersecretion, and high serum levels of 
IgE [Wills-Karp, 1999; Busse and Lemanske, 2001; Davies et al, 2003]. For many 
years, bronchial asthma has been explained by the aberrant excitation of Th2 cells 
[Elias et al, 2003; Umetsii et al, 2002] because inactivation of GATA-3 reduced 
airway inflammation and hypersensitivity in experimentally induced asthma of mice 
[Zhang, 1999], and IFN-y-producing Thl cells were regarded to prevent asthma 
[Barnes, 1999]. However, recent studies have shown that the co-presence of Thl cells 
aggravates the bronchial asthma. Allergen challenge induces asthma in mice 
transferred with the allergen-specific Th2 cells. However, co-transfer of 
4 
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allergen-specific Thl cells does not protect from these types of asthma [Randolph et 
al, 1999]. Allergen-specific Thl cells also fail to counterbalance Th2 cell-mediated 
AHR [Hansen et al, 1999]. Thl and Th2 responses together cause severe respiratory 
inflammation, suggesting the importance of both Thl and Th2 cytokines. Indeed, 
combination of IFN-y and IL-13 induces severe bronchial asthma in mice [Ford, 
2001]. It has been demonstrated that patients with bronchia丨 asthma, particularly those 
with long history of bronchial asthma, show the co-presence of Thl and Th2 
responses in their injured airway [Hotzman et al, 1996; Krug, 1996]. Thus, bronchial 
asthma may be categorized into two types: Th2 cell-induced asthma and Thl/Th2 cell 
mixed-type asthma. 
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1.2 Cytokines as modulator in Th lymphocyte activation 
Th differentiation can be initiated by cytokines. Cytokines are small extracellular 
signal proteins which exert their effects either by paracrine or autocrine manner. Other 
cellular responses regulated by cytokines include activation, proliferation, chemotaxis, 
apoptosis, synthesis and release of other cytokines and mediators [Chung et al, 1999]. 
1.2.1 IL-18 
IL-18, formerly called IFN-y-inducing factor, is a proinflammatory cytokine 
related to the IL-1 family that is produced by Kupffer cells, activated macrophages, 
keratinocytes, intestinal epithelial cells, osteoblasts and adrenal cortex cells [Dinarello, 
1999]. It plays an important role in the innate immunity and Thl response to toxic 
shock and shares functional similarities with IL-12 [Dinarello, 1999]. IL-18 
receptors are selectively expressed on murine Thl cells but not Th2 cells [Xu et al, 
1998]. 
The primary functions of IL-18 include the induction of IFN-y and tumor 
necrosis factor (TNF)-a in T cells and natural killer (NK) cells [Puren et al, 1998, 
Tanaka et al, 2001], IL-8 in eosinophils [Wang et al, 2001], up-regulation of Thl 
cytokines including IL-2, IFN-y [Dinarello, 1999] and Th2 cytokines IL-5, IL-6 and 
granulocyte macrophage colony-stimulating factor (GM-CSF) [Ogura et al, 2001], 
stimulation of the proliferation of activated T cells [Dinarello, 1999], and 
enhancement of Fas ligand expression in NK and cytotoxic T lymphocytes [Dao et al, 
1996]. 
Elevated IL-18 levels have also been demonstrated in the urine of nephrotic 
patients [Matsumoto et al, 2001], serum of patients with MS [Nicoletti et al, 2001], 
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IDDM [Nicoletti, 2001], viral infection [Harandi et al, 2001], allergic asthma [Wong 
et al, 2001], and systemic lupus erythematosus (SLE) [Wong et al, 2000]. 
1.2.2 IL-25 
IL-25 (IL-17E) is a novel Th2 proinflammatory cytokine belonging to a newly 
discovered member of the IL-17 cytokine family. Its receptor is IL-17 receptor 
homology 1 (Rhl) [Lee et al, 2001; Moseley et al, 2003]. IL-25 is secreted by CD4+ 
activated memory (CD45+RO+) T cells [Kempuraj et al, 2003]. 
Intranasal administration of IL-25 has been shown to induce the production of 
Th2 cytokines and the expression of chemokine eotaxin mRNA in the murine lung 
[Fort et al, 2001; Hurst, 2002], resulting in Th2-like response marked by increased 
serum IgE, IgGl and IgA concentrations, eosinophilia in blood, bronchoalveolar 
lavage, and lung tissue, and the development of pathological changes including 
eosinophilic infiltration, epithelial cell hyperplasia/hypertrophy, increased mucus 
secretion and airway hyperreactivity in mice [Fort et al, 2001; Hurst et al, 2002]. It is 
reported that bone marrow derived mast cells could generate large amounts of IL-25 
when the cells were challenged by IgE cross-linking, thereby indicating that mast 
cells may affect Th2 immunoresponse through the production of IL-25 [Ikeda et al, 
2003]. Therefore, IL-25 plays an important role to provoke allergic inflammation, 
especially in IgE-dependent atopic diseases and eosinophil-mediated late phase 
allergic reactions [Wong et al, 2005]. 
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1.3 Surface marker expression in Th lymphocytes 
1.3.1 Adhesion molecules 
Adhesion molecules are important for leukocyte endothelial attachment and 
migration to sites of inflammation. The leukocyte function-associated antigen 
(LFA)-l integrin molecule and intracellular cell adhesion molecule (ICAM)-l are 
constitutively expressed on the Th cell surface. 
(1) LFA-1 
LFA-1 is a p2 integrin comprising a non-covalently linked heterodimer between 
a unique a chain (CD 11 a) and (3 chain (CD 18). LFA-1 interacts primarily with 
ICAM-1 but also with ICAM-2 and -3 [Ostermann et al, 2002]. It has been reported 
that a rapid conformational change of LFA-1 following T cell activation to an 
"adhesive" state occurs, allowing LFA-1 binding to ICAM-1-expressing targets, such 
as APCs and endothelial cells [Crucian et al, 2006]. Besides, LFA-1 has been shown 
to induce the trafficking of T cells to the lung following Mycobacterium tuberculosis 
infection [Ghosh et al, 2006]. LFA-1/ICAM-1 interactions during transendothelial 
migration also enhance the survival of activated T lymphocytes at sites of 
inflammation [Borthwick et al, 2003]. 
(2) ICAM-1 
ICAM-1 is a 90 kD inducible surface glycoprotein containing five Ig-like 
domains [Staunton et al, 1988]. It binds to LFA-1, macrophage antigen (MAC)-l, 
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fibrinogen, hyaluronan and CD43 [van de Stolpe et al, 1996]. It is an important 
marker of immune activation in bronchial asthma, allergic rhinitis 
[Grzelewska-Rzymowska et al, 2004] and inflammatory bowel disease [Papa et al, 
2004]. ICAM-1 interaction with LFA-1 and MAC-1 on the surface of eosinophils and 
mast cells is important for their transendothelial migration to sites of inflammation. 
However, its role on Th cells during inflammation is seldom reported. Instead, 
previous study has shown that anti-ICAM-1 monoclonal antibody inhibits Th cell 
response to recall antigens [Buckle and Hogg, 1990]. Recently, ICAM-1 has also been 
reported to act as co-stimulatory ligand on Th cells [Lebedeva et al, 2005]. 
1.3.2 Cytokine and chemokine receptors 
Cellular responses such as activation, proliferation, differentiation, chemotaxis 
and apoptosis are induced by binding of cytokines and chemokines with their specific 
receptors on target cells. Thus, they are important for extracellular communications. 
(1) IL-2R 
IL-2 receptor (IL-2R) is composed of three subunits. IL-2Ra is essential for 
proper cell responses but not signal transduction due to its short cytoplasmic tail. In 
contrast, IL-2RP and y together are necessary and sufficient for effective signal 
transduction [Gaffen, 2001]. IL-2 is a critical growth factor for T cells which 
promotes cell differentiation and proliferation. Therefore, anti-IL-2R antibody therapy 
is an exciting approach to the prevention of acute rejection after renal allograft 
transplantation, which specifically blocks IL-2Ra on activated T cells 
[Swiatecka-Urban, 2003]. Overexpression of IL-2Ra in human squamous carcinoma 
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cell line is also associated with increased proliferation, drug resistance, and 
transforming ability [Kuhn et al, 2003]. In addition, IL-2Ra is absolutely required for 
the development of the regulatory CD25+CD4+ T cells that control peripheral CD4 T 
cell homeostasis [Almeida et al, 2002]. 
(2) CCR5 
CC chemokine receptor (CCR)5 is a high-affinity receptor for macrophage 
inflammatory protein (MlP)-la, MIP-lp and Regulated upon activation normal T cell 
expressed and secreted (RANTES). It is expressed on macrophages, DCs and T cells. 
CCR5 is responsible for leukocyte recruitment to inflammatory sites [Loetscher et al, 
1998]. It has been reported that IL-12 can induce CCR5 expression on T cells upon 
costimulation [Yang et al, 2001]. Besides, CCR5 is predominantly expressed on Thl 
cells infiltrating into the inflamed synovial tissue of RA [Ueno et al, 2005] and MS 
[Balashov et al, 1999]. The expression of CCR5 may therefore be related to 
autoimmune diseases. As CCR5 can act as coreceptors for human immunodeficiency 
virus (HIV) infection in human leukocytes [Choe et al, 1996], it has been regarded as 
a gateway for both inflammation and infection [Premack et al, 1996]. 
(3) CXCR3 
CXC chemokine receptor (CXCR)3 binds to interferon-y inducible protein 
(IP-10), monokine induced by interferon-丫 (MIG), and interferon-inducible T-cell 
alpha chemoattractant (I-TAC). It is preferentially expressed on activated Thl cells, B 
cells and NK cells. CXCR3 expression and function are enhanced markedly following 
IL-2 stimulation [Loetscher et al, 1998]. CXCR3 can mediate the trafficking of 
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activated T cells and NK cells to inflammatory sites in response to IP-10, MIG and 
I-TAC. Increased expression of CXCR3 on lymphocytes has been reported in MS 
[Sorensen et al, 1999], RA [Qin et al, 1998; Loetscher et al, 1998], inflammatory 
infiltrates in ulcerative colitis and chronic vaginitis [Qin et al, 1998]. 
1.3.3 Costimulatory molecules 
Costimulatory molecules are cell surface glycoproteins that can direct, modulate 
and fine-tune TCR signals [Chen et al, 2006]. 
(1) ICOS 
Inducible costimulator (ICOS) is expressed on activated T cells. It specifically 
binds to B7-related protein (B7RP)-1 on B cells and macrophages [Yoshinaga et al, 
1999]. ICOS can enhance the proliferation and secretion of cytokines from Th cells 
[Grimbacher et al, 2003]. Besides, ICOS was highly expressed on Th2 cells but not 
Thl cells [Coyle et al, 2000]. The ICOS-mediated signaling has also been reported to 
contribute to inflammatory responses through the regulation of IL-4 and chemokine 
receptors CCR3, CCR4 and CCR8 [Chen and Shi, 2006]. In experimental asthma, 
ICOS blockade can attenuate disease or reduce eosinophilia and IgE levels [Tafuri et 
al, 2001; Gonzaloet al, 2001]. 
(2) CTLA-4 
Cytotoxic T lymphocyte-associated (CTLA)-4 delivers inhibitory signals for T 
cell activation and has a greater binding affinity for B7 molecules on APCs than 
11 
Chapter I Introduction 
CD28 [Walunas et al, 1994]. In the quiescent state, CTLA-4 is stored in intracellular 
vesicles. Upon activation, these vesicles are rapidly mobilized to the cell surface, 
allowing expression of CTLA-4 and competing with CD28 for B7-binding sites 
[Vaidya et al, 2004]. In murine models, administration of CTLA-4-blocking 
antibodies augments anti-tumour immunity [Leach et al, 1996], exacerbates 
experimental allergic encephalitis [Perrin et al, 1996] and precipitates the onset of 
diabetes in the TCR transgenic non-obese diabetic mouse [Luhder et al, 1998]. In 
addition, soluble CTLA-4 has been reported to prolong the survival of transplant 
grafts [Lenschow et al, 1992] and ameliorates different experimental autoimmune 
disorders, including lupus [Finck et al, 1994] and diabetes [Lenschow et al, 1995]. 
Finally, the engagement of CTLA-4 with ligands of B7 family inhibits interleukin-2 
production, arrests the progression of activation-induced T-cell cycling [Krummel et 
al, 1996] and induces apoptosis of activated T cells [Scheipers et al, 1998; Gribben et 
al, 1995]. 
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1.4 Cytokine and chemokine release from Th lymphocytes 
1.4.1 Thl cytokines 
Thl cells contribute to cell-mediated immunity [Mullen et al, 2001]. By 
producing Thl cytokines, Thl cells fight against viruses and other intracellular 
pathogens, eliminate cancerous cells and stimulate DTH skin reactions. 
(1) IFN-y 
IFN-y, a potent proinflammatory cytokine, is produced by activated T and NK 
cells. Being the principal Thl effector cytokine, IFN-y can induce IL-12 production 
from DCs and macrophages [Snijders et al, 1998, Szabo et al, 2003]. While inhibiting 
the production of Th2 cytokines IL-4 and IL-5, IFN-y activates T-bet protein, the 
Thl-specific transcription factor [Lighvani et al, 2001; Afkarian et al, 2002]. It has 
been reported that IFN-y can completely abrogate the antigen presenting capacity of 
mast cells [Farrar & Schreiber, 1993; Frandji et al, 1995]. Therefore, mast cells can 
act as APCs in the absence of IFN-y and elicit Th2 responses by releasing IL-4 in 
allergic inflammation [Hamid et al, 1991; Frandji et al, 1995, Constant and Bottomly, 
1997]. Finally, IFN-y can also decrease the expression of CCR3 which was an 
important inducer of eosinophil differentiation [Lamkhioued et al, 2003] 
(2) TNF-a 
TNF-a is produced by T cells, mast cells, epithelial cells and mainly by 
macrophages. It interacts through TNF-Rl and TNF-R2, which are distributed on 
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nearly all cells except erythrocytes and resting T cells. Soluble TNF has greater 
affinity for TNF-Rl while transmembrane TNF has equal affinity for the two 
receptors [Kast, 2005]. TNF-a has been demonstrated to stimulate airway epithelial 
cells to produce RANTES, IL-8, and GM-CSF [Berkman et al, 1995; Cromwell et al, 
1992], and eosinophils to produce GM-CSF and eotaxin [Ternkin et al, 2001]. It is 
also shown to up-regulate the expression of adhesion molecules such as E-selectin, 
ICAM-1 and vascular cell adhesion molecule (VCAM)-l which can facilitate 
inflammatory cell migration [Thomas, 2001]. 
1.4.2 Th2 cytokines 
In contrast to Thl cells, Th2 cells are responsible for humoral responses [Das et 
al, 2001]. Th2 cytokines can up-regulate antibody production to fight against 
extracellular organisms. 
( I ) 丨 L-5 
IL-5 is mainly produced by activated Th2 cells, mast cells and eosinophils 
[Takatsu, 2004; Dubucquoi et al, 1994]. IL-5 preferentially acts on eosinophils to 
prolong maturation, survival and activation [Takatsu, 2004]. It also appears to be the 
major cytokine involved in the development of eosinophilia and tissue remodeling in 
allergic asthma [Rothenberg, 1998]. Besides, IL-5 is implicated in the priming of 
mature eosinophils to a range of stimuli that activate chemotaxis, degranulation, 
adhesion and activation of superoxide production [Giembycz and Lindsay, 1999]. 
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(2) IL-6 
IL-6 is mainly produced by macrophages, fibroblasts, endothelial and epithelial 
cells. It can also be synthesized by T cells, B cells, mast cells and eosinophils [Chung 
& Barnes, 1999; Akira et al, 1993]. IL-6 is involved in T cell activation, growth and 
differentiation. It is a terminal differentiation factor for B cells and an important 
cofactor for IL-4 dependent IgE synthesis from B cells [Akira et al, 1993]. In addition, 
IL-6 can regulate leukocyte apoptosis [McLoughlin et al, 2003] and the expression of 
inflammatory chemokines and adhesion molecules [Baggiolini, 1998]. 
(3) IL-IO 
IL-10 is produced by activated monocytes and T cells. It possesses many 
immunosuppressive properties including inhibition of IL-2 [de Waal Malefyt et al, 
1993; Groux et al, 1996] and dendritic cell maturation [Steinbrink et al, 1997]. IL-10 
has been reported to induce T cell anergy [Groux et al, 1996] and contribute to the 
generation of regulatory T (Treg) cells [Groux et al, 1997]. Evidence also suggests 
that IL-10 is required for the maintenance and functions of Treg cells [Read and 
Powrie, 2001]. Besides, an imbalance between IL-2 and IL-10 production by Th cells 
is responsible for the development of autoimmune diseases [Veiopoulou et al, 2004]. 
1.4.3 Chemokines 
Chemokines, a group of small (8 to 12 kDa) molecules, can induce chemotaxis in 
a variety of cells including neutrophils, monocytes, lymphocytes, eosinophils, 
fibroblasts, and keratinocytes. They are central for the recruitment of specific 
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leukocyte subpopulations [Moser et al, 2004]. Most chemokines have four 
characteristic N-terminal cysteines. However, their functions are dependent on the 
motif displayed by the first two cysteines. Chemokines are classified into four groups, 
namely CC, CXC, C and C X 3 C [Luster, 1998]. 
(1) IP-10 
IP-10，a CXC chemokine, exhibits its effect through the CXCR3 receptor 
expressed on Thl cells, monocytes and neutrophils. Therefore, IP-10 can selectively 
chemoattract these cells [Zeng et al, 2005]. Increased levels of IP-10 are found in 
psoriatic plaques characterized by the infiltration of neutrophils [Gottlieb et al, 1988]. 
IP-10 has also been reported to inhibit cytokine-stimulated hematopoietic progenitor 
cell proliferation. Additionally, it is angiostatic and mitogenic for vascular smooth 
muscle cells [Yang et al, 2004]. Finally, evidence showed that IP-10 may play an 
important role in DTH responses [Akahira-Azuma et al, 2004]. 
(2) MIG 
MIG, a CXC chemokine, binds to CXCR3 expressed mainly on T cells and NK 
cells [Farber, 1997]. It responds primarily to IFN-y. MIG has been shown to induce 
adhesion of activated T cells to endothelial cells [Liao et al, 1995]. Besides, MIG 
contributes to the accumulation of CXCR3-expressing eosinophils in the lungs of 
patients with chronic eosinophilic pneumonia, and modulate the eosinophilic 
inflammation of the lung [Katoh et al, 2005]. MIG has also been found to play 
important roles in transmigration, relocation, differentiation, and maturation of 
CD34+ hematopoietic progenitors [Jinquan et al, 2000]. 
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(3) RANTES 
RANTES is a CC chemokine binding to CCRl, CCR3 and CCR5 receptors 
which are expressed on T cells, monocytes, eosinophils and basophils. Therefore, 
RANTES is chemotactic for these cell types and plays an active role in recruiting 
leukocytes into inflammatory sites [Zhang et al, 1994]. RANTES has been reported to 
activate eosinophils to release eosinophilic cationic protein which is associated with 
asthma and allergic rhinitis [Lampinen et al, 2004]. It also increases the adherence of 
monocytes to endothelial cells [von Hundelshausen et al, 2005] and activates human 
basophils to release histamines [Conti et al, 1997]. 
(4) IL-8 
IL-8 is a proinflammatory CXC chemokine binding to CXCRl and CXCR2 
mainly expressed on neutrophils. A significant correlation between plasma IL-8 
concentration and neutrophil infiltration in acute inflammation has been reported 
[Huber et al, 1991]. Besides, IL-8 can regulate various biological functions of 
neutrophils including chemotaxis, degranulation, superoxide production, and 
expression of adhesion molecules. In patients with hypereosinophilic syndrome, IL-8 
can induce shape change and release of peroxidase from eosinophils [Kernen et al, 
1991]. 
(5) MlP-la 
MlP-la is a CC chemokine. It exerts its effect through CCRl and CCR5 [Rossi 
et al, 2000]. MlP-la has been reported to preferentially attract CD4+ T cells [Taub et 
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al, 1993]. It is also involved in the activation of human leukocytes, such as 
neutrophils, eosinophils and basophils, as well as acute neutrophilic inflammation 
[Schall et al, 1993]. Besides, it can augment the adhesion of CD8+ T cells to 
VCAM-1 -expressing endothelial cells [Tanaka et al, 1993]. 
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1.5 Intracellular signaling pathways in Th lymphocytes 
In recent years, there have been increasing interests in the elucidation of the 
regulatory mechanisms of Th cell activation, differentiation, chemotaxis, adhesion, 
cytokine and chemokine productions, etc. One way to demonstrate the regulatory 
mechanisms is to study the activation of different intracellular signal transduction 
pathways under different stimulations. Among them, p38 mitogen-activated protein 
kinases (MARK), extracellular-regulated protein kinase (ERK), c-Jun NH2-terminal 
kinase (JNK) and nuclear factor-kappa B (NF-KB) have been shown to regulate 
inflammatory responses [Wong et al, 2004]. 
1.5.1 p38 MARK pathway 
The p38 MAPK signaling pathway has been shown to be an important mediator 
of inflammatory processes. Endotoxic lipopolysaccharide and proinflammatory 
cytokines cause marked activation of p38 MAPK [Raingeaud et al, 1995]. In addition, 
specific inhibitors of p38 MAPK (pyridinyl imidazole drugs) inhibit the secretion of 
inflammatory cytokines [Lee et al, 1994]. Growing evidence supports the role of the 
p38 pathway in Thl differentiation and cytokine production. For example, transgenic 
animal models demonstrate that the p38 MAPK pathway regulates transcription of the 
IFN-Y gene by Thl cells [Rincon et al, 1998]. 
Upon activation, p38 MAPK is subjected to dual phosphorylation at the 
Thr-Gly-Tyr motif. The phosphorylated p38 then activates a variety of transcription 
factor including activating transcription factor (ATF)-2, signal transducer and 
activators of transcription (STAT)-l, and cAMP responsive element binding protein 
(CREB). On the other hand, the upstream kinases acting on p38 include MAPK 
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kinases (MKK) 3 and 6 which are in turn activated by MAPK/ERK kinases (MEKKs) 
[Roux et al, 2004]. 
1.5.2 ERK pathway 
The ERK pathway was first identified downstream of oncogenic Ras. It is 
involved in the regulation of cell growth and differentiation [Elben et al, 2002; 
Hashimoto et al, 2000]. ERK is also important for T cell activation and deficient ERK 
activation has been reported in anergized T cell clones [Li et al, 1996; Fields et al, 
1996]. By using dominant H-RAS transgenic mice in which ERK activation by TCR 
was severely compromised, Yamashita and colleagues showed that this pathway is 
required for Th2 differentiation [Yamashita et al, 1999]. 
Ras is activated in response to agonist stimulation and recruits Raf protein 
kinases to the plasma membrane [Leevers et al, 1994]. Raf proteins phosphorylate and 
activate ERK kinases (MEKs), which then phosphorylate and activate the two ERK 
proteins, ERKl and ERK2. Besides, MEKs can serve as cytoplasmic anchors for the 
ERKs, holding the ERKs in the cytoplasm when the signaling pathway is inactive 
[Fukuda et al, 1997]. Stimulation of the pathway results in the phosphorylation of the 
ERKs and their dimerization and translocation to the nucleus and other sites of action, 
where they phosphorylate transcription factors for bringing out biological responses 
[Eblen et al, 2002]. 
1.5.3 JNK pathway 
JNK, also known as stress-activated MAP kinase, phosphorylates the prototypic 
c-Jun at Ser-63 and Ser-73 and increases activator protein (AP)-l transcription 
2 0 
Chapter I Introduction 
activity. Recently, a number of other substrates of JNK have been identified, 
including AP-1 transcription factor family members JunB, JunD and ATF2, nuclear 
factor of activated T cells (NFAT) family members NFAT4, NFATc and 
anti-apoptotic bcl-2 family members bcl-2 and bcl-xl [Davis, 2000; Ip et al, 1998]. 
JNK has been widely implicated in a number of physiological processes, 
including embryonic development, cell survival/apoptosis, and proliferation [Davis, 
2000; Ip et al, 1998]. JNK may also have important functional roles in Thl cells. It 
has been reported Thl cells have highly inducible JNK activity compared to Th2 cells 
[Rincon et al, 1997; Yang et al, 1998] 
1.5.4 NF- ft B pathway 
N F - K B appears to be particularly important in cytokine-mediated inflammatory 
and immune responses. Activation of NF-KB can enhance the transcription of a 
variety of genes, including cytokines and growth factors, adhesion molecules, 
immunoreceptors, and acute-phase proteins [Blackwell et al, 1997]. It is highly 
activated at inflammation tissues in various diseases including allergic asthma by 
enhancing the recruitment of inflammatory cells and production of pro-inflammatory 
cytokines [Ip et al, 2003]. Inhibition of NF-KB activity is effective at controlling 
inflammatory diseases in several animal models [Wong et al, 2003]. 
In unstimulated cells, N F - K B is localized to the cytoplasm because of binding 
to inhibitory protein, IKB [Baldwin, 1996]. When the cell is activated, specific IKB 
kinase phosphorylate IKB, leading to the rapid addition of ubiquitin and subsequent 
degradation in proteasome by the action of protease [Baldwin, 1996]. This allows 
N F - K B to be transported to the cell nucleus, where its dimers are free to bind to 
specific motifs in the promoter regions of various genes, and initiate transcription. 
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1.6 Pharmacological intervention of signaling pathways 
As mentioned above, intracellular signaling pathways play important roles in 
coordinating genes that control immune responses [Dong et al, 2002; Pomerantz et al, 
2002]. ERK and p38 MAPK can regulate growth and differentiation signals and 
mediate inflammatory and stress responses [Kyriakis et al, 2001], while N F - K B 
activation is correlated with inflammatory diseases, such as rheumatoid arthritis, 
inflammatory bowel disease and allergic asthma [Li et al, 2002]. Therefore, inhibition 
of these pathways may have implications for treating inflammatory diseases 
[Kowalski et al, 2001]. 
At present, a variety of pharmacological agents act at different levels to inhibit 
proper cellular responses. For example, they directly affect cytokine or growth factor 
receptor function by binding and acting as agonists or antagonists or by inhibiting the 
receptor associated enzymatic activity. Besides, some agents inhibit intermediate steps 
between the receptor and transcription, including protein kinases and 
phosphodiesterases [Saklatvala et al, 2004]. Others have been reported to bind to 
transcription factors and modulate their activity [Young, 1998]. In fact, several 
pharmacological agents have already been established for blocking signaling 
pathways which regulate different biological functions of eosinophils [Wong et al, 
2004]. Table 1.2 shows the inhibitors of intracellular signaling molecules as potential 
therapeutic agents of inflammatory diseases. 
In future, following advances in elucidation of the molecular and cellular 
mechanisms of inflammatory diseases, more potential therapeutic strategies will be 
developed. 
2 2 
Chapter I Introduction 
Table 1.1 Possible therapeutic use of signaling pathway inhibitors 
Target molecules Inhibitors 
JAK2 AG-490 
ERK PD098059 
Lyn Lyn-binding peptide 
MEK U0126 
N K - K B MG-132, gliotoxin 
P38 MAPK SB 203580, SB 239063 
PI3K Wortmannin, LY294002 
PKA H89 
PKC Staurosporine, RO-32-0432 
Syk Anti-sense oligodeoxynucleotides 
Tyk Genistein 
Wong et al, 2004 
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1.7 Aims and scope of the study 
Optimal activation of T lymphocytes requires the engagement of the TCR/CD3 
complex with MHC, as well as the costimulatory interaction between the B7 family 
ligands, B7-1 (CD80), B7-2 (CD86), and B7RP-1, on antigen presenting cells and 
their corresponding receptors CD28, CTLA-4, and ICOS on T cells [Rudd, 1996; 
Weiss et al, 1994]. Upon T cell costimulation, a variety of cytokines and chemokines 
can be induced by various Thl/2 cytokines for the subsequent inflammation. The 
production of Th2 cytokines IL-4 and IL-5 causes eosinophilia and elevated serum 
total and specific IgE concentration in allergic inflammation, and Thl cytokines such 
as IFN-y and TNF-a can activate the cell-mediated inflammation [Wong et al, 2001, 
Wong and Lam 2003]. T cell activation by costimulatory interaction, particular CD28, 
plays an important role in the immunopathogenesis of inflammation such as allergic 
inflammation and infection [Wong et al, 2005; Deurloo et al, 2003; Alegre et al, 2001]. 
Therefore, allergen-activated CD3 and ligation of costimulatory receptor CD28 
coordinated signaling is essential for the initiation, clonal expansion and effector 
function of allergen-activated T cells in allergic inflammation. 
The airway of asthmatic patients, particularly those with long history of 
bronchial asthma, often shows co-presence of Thl and Th2 cells, increased eosinophil 
and neutrophil numbers and elevated IL-18, IL-25, IFN-y, IL-5, IL-6 and IL-8 levels 
[Humbles et al, 2004; Wong et al, 2005; Wong et al, 2001 ； Cembrzynska-Nowak et al, 
1993; Ordonez et al, 2000]. IL-18 is a pro-inflammatory cytokine that enhances IFN-y 
production by Thl cells in the presence of anti-CD3 antibody [Dinarello, 1999; 
Nakanishi et al, 2001]. Another study has demonstrated that anti-CD3 and IL-18 could 
activate Thl cells but not Th2 cells to produce both Thl and Th2 cytokines including 
IFN-Y, IL-13 , GM-CSF and IL-8 [Hata et al, 2004]. On the other hand, IL-25, a novel 
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Th2 cytokine, has been shown to induce the production of Th2 cytokines [Fort et al, 
2001]. IL-25 was also shown to play an important role to provoke allergic 
inflammation, especially in IgE-dependent atopic diseases and eosinophil-mediated 
late phase allergic reactions [Wong et al, 2005]. 
Signal transduction studies using Jurkat T cell lines demonstrated that 
costimulation of CD3 and CD28 can activate TCR signaling pathways including 
MAPK [Kim and White, 2006]. IL-18 could induce IFN-y in a differentiated Thl cell 
population through the p38 MAPK pathway [Yu et al, 2003]. Previous results from 
our group have suggested that IL-25-induced release of cytokines and chemokines 
from eosinophils is mediated by the combined activation of MAPK and N F - K B 
pathways [Wong et al, 2005]. However, the optimal activation of CD28 costimulated 
Th cells by IL-18 and IL-25 has not been studied yet. The present study using IL-18 
and IL-25 for the activation of Th cells mimicked the airway inflammation of 
bronchial asthma. In an attempt to elucidate the detailed mechanisms by which Thl 
related IL-18 and Th2 related IL-25 induce the release of Thl/2 cytokines and 
chemokines in costimulated Th cells, the intracellular MAPK and N F - K B activities 
upon the activation were investigated in the present study by using inhibitors 
BAY 11-7082, PD98059, SP600125 and SB203580. 
In view of recent advances in the application of M A P K and N F - K B inhibitors as 
potential anti-inflammatory agents in asthma [Duan et al, 2004, 2005; Markarov, 2000; 
Chialda et al, 2005], our study of differential mechanisms on the activation of Th cells 
should provide new insights on the development of therapeutic intervention for 
inflammatory diseases, particularly in severe asthma that usually contains both the 
activation of Thl and Th2 cells in the local inflammatory sites in the lungs. 
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Chapter 2 
Materials and Methods 
2.1 Materials 
2.1.1 Blood samples 
% 
(1) Human buffy coat 
Fresh human buffy coat was provided by the Hong Kong Red Cross Blood 
Transfusion Service. Th cells were purified from buffy coat within 24 h after 
donation. 
(2) Atopic subjects 
One hundred ml blood sample was collected from each of a group of atopic 
subjects for Th cell purification. Their plasma samples were subjected to total and 
specific IgE screening of 6 common allergens including food mix, house dust mite, 
cat, dog, cockroach and mould mix. Recruited atopic subjects were found to be 
sensitive to one or more allergens. 
2.1.2 Media and reagents for cell culture 
(1) Culture medium 
RPMI 1640 Medium containing L-glutamine at pH 7.2 was used to culture Th 
cells. This culture medium was purchased from Gibco Invitrogen Corp, CA, USA. 
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(2) Serum supplements 
Fetal calf serum (FCS) was purchased from Hyclone Co, MA, USA. It had been 
tested for low endotoxin (<10 EU/ml) and hemoglobin (<10 mg/ml) levels. 
Heat-inactivated fetal calf serum (HI-FCS) was prepared as 50 ml aliquots by heating 
at 56°C for 30 min and stored at -20°C until use. 
(3) Phosphate-buffered-saline (PBS) solution 
(a) Sterilized PBS solution (0.2 g potassium chloride, 8 g sodium chloride and 1.15 g 
dibasic sodium phosphate in 1 L) at pH 7.4 was purchased from Gibco. 
(b) PBS powder (Sigma Chemicals Co., MO, USA) was dissolved in 1 L double 
distilled water. The pH was adjusted to 7.4 by 1 M HCl or 1 M NaOH and then 
autoclaved at 121°C for 15 min. 
(4) Endotoxin-free solution 
Cell culture medium free of detectable LPS (<0.1 EU/mL) was purchased from 
Gibco Laboratories, Grand Island, NY, USA. All other solutions were prepared using 
pyrogen-free water and sterile polypropylene plasticware. No solution contained 
detectable LPS, as determined by the Limulus amoebocyte lysate assay (sensitivity 
limit 12 pg/ml; Cambrex Bio Science Walkersville Inc, MD, USA) 
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2.1.3 Antibodies for co-stimulation of Th cells 
Purified mouse anti-human monoclonal antibody (mAb) CD3 and CD28 
antibodies were purchased from BD Pharmingen Corp, CA, USA. The antibodies, at 
the concentration of 1 mg/ml, were purified from tissue culture supernatant by affinity 
chromatography. They contain no azide and were kept at 4 
2.1.4 Recombinant human cytokines 
Recombinant human IL-18 and IL-25 were purchased from Medical & 
Biological Laboratories Co Ltd, Nagoya, Japan. It was a lyophilized recombinant 
protein derived from E. coll The cytokine was reconstituted to 10 |ig/ml in sterilized 
PBS supplemented with 0.5 % BSA. Aliquots of 20 |il were kept a t - 8 0 � C until use. 
2.1.5 Signaling pathway inhibitors: SB203580, PD98035, SP600125 and 
BAY117082 
These were purchased from Calbiochem, San Diego, California, USA. 
SB203580 is a pale yellow solid which is a water-soluble form of the potent selective 
p38 MAPK inhibitor. PD98058, a pale yellow solid, is a selective and cell permeable 
inhibitor of MEK. SP600125, a yellow orange solid, is a potent, cell-permeable, 
selective, and reversible inhibitor of JNK. BAY 117082 is an off-white crystalline 
solid that can selectively and irreversibly inhibit the IKB kinase and hence the 
subsequent phosphorylation of IKB-OI, therefore reducing the release of free NF-KB. 
PD98058, SP600125 and BAY 117082 were dissolved in dimethyl sulfoxide (DMSO). 
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In all studies, the concentration of DMSO used was 0.1 % (vol/vol). SB203580 was 
reconstituted in distilled water to 10 mM. Aliquots of inhibitors were stored at —80°C 
until use. 
2.1.6 Monoclonal antibodies and reagents for immunofluorescent staining 
(1) Monoclonal antibodies 
Brand Name Format Clone Isotype Usage (per 
5 X lO5 cells 
BD Pharmingen CD4 FITC SK3 Mouse IgG, 10 … 
BD Pharmingen 1L-2R PE 2A3 Mouse IgG, 
(CD25) 
R&D Systems iL-18Ra PE 70625 Mouse IgGi ⑴ 
BD Pharmingen cCR5 FITC 2D7 Mouse IgGaa ⑴ … 
BD Pharmingen cXCR3 APC IC6 Mouse IgG, 1 ( M 
BD Pharmingen [FA-l FITC 6.7 Mouse IgG, lOjil 
(CD18) 
R&D Systems jcaM-I FITC BBIG-11 Mouse IgG, 5^1 
BD Pharmingen j cOS PE DX29 Mouse IgG, 10^1 
(CD278) 
BD Pharmingen cTLA-4 APC BNI3 Mouse IgG^a lOfil 
(CD 152) 
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BD Pharmingen ^Q FITC MOPC-21 Mouse IgGi lOjil 
BD Pharmingen 置匚 FI丁G G155-178 Mouse IgG2a 10 [il 
BD Pharmingen 丨^^  pg MOPC-21 Mouse IgGi 10 |il 
BD Pharmingen AP^^ MOPC-21 Mouse IgGi 10 \x\ 
BD Pharmingen APC G155-178 Mouse IgG2a 10 |il 
(2) Human Serum 
Human serum for blocking procedure in immunofluorescent staining was 
obtained from venous blood of Chinese healthy volunteers. 
(3) FACS Flow sheath fluid 
The sheath fluid is a ready-to-use product purchased from BD Pharmingen Corp. 
It is a balanced electrolyte solution containing sodium chloride, potassium chloride, 
disodium EDTA, sodium fluoride and anti-microbial agent. The solution was kept at 
room temperature. 
(4) FACS medium 
The buffer contains 0.5 % BSA and 0.01 % sodium azide (NaNs) in 1 X PBS. It 
was kept at 4°C and used for washing in immunofluorescent staining. 
(5) Paraformaldehye (1 %) in PBS 
Paraformaldehyde powder (10 g) purchased from Sigma Chemical Co was 
dissolved in 1 L 1 X PBS for cell fixation. The solution was titrated to pH 7.4 and 
kept at 4°C until use. 
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2.1.7 Reagents and buffers for the purification of human Th lymphocytes 
(1) Magnetic cell sorting system (MACS) 
The MACS was purchased from Miltenyi Biotec, Bergisch Gladbach, Germany. 
It consists of a MidiMACS Separation Unit, a MACS MultiStand and a LS Separation 
Column which can separate a maximum of 2 x 1 t o t a l cells and 10^ magnetically 
labeled cells. 
(2) CD4+ T cell isolation kit II 
The CD4+ T Cell Isolation Kit II purchased from Miltenyi Biotec consists of 
biotin-conjugated antibodies and anti-biotin microbeads. It is an indirect magnetic 
labeling system for the isolation of untouched CD4+ T helper cells from human 
peripheral blood mononuclear cells (PBMC). 
(3) Ficoll-Paque solution 
Ficoll-Paque containing 5.7 g Ficoll 400，9 g sodium diatrizoate and calcium 
EDTA in 100 ml water (density = 1.077 g/ml) was purchased from Amersham 
Pharmacia Biotech Ltd, Uppsala, Sweden. 
(4) Red blood cell (RBC) lysiiig buffer 
Sterilized 0.5 X PBS was used to remove excess RBC in PBMC prior to Th cell 
purification. 
(5) Wash buffer 
Sterilized 1 X PBS supplemented with 2 % FCS was used as washing buffer and 
was kept at 4°C until use. 
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2.1.8 Reagents and buffers for protein array 
Ray Bio human cytokine array V was purchased from RayBiotech Inc, GA, USA. 
It was used to assess the expression profile of 79 different cytokines in culture 
supernatant of Th cells semiquantitatively. 
2.1.9 Reagents and buffers for Thl/2 cytokine and chemokine detection 
(1) Cytometric Bead Array (CBA) kit 
IL-8, RANTES, MIG and IP-10 concentrations in culture supernatant were 
measured by Chemokine Human CBA kit I，whereas TNF-a, IL-5, IL-6, IL-10 and 
MlP- la were measured by CBA Flex Sets using a FACSCalibur flow cytometer 
(Becton Dickinson, CA, USA). The kits contain cytometer setup beads, capture beads, 
PE conjugated detection reagents, standards and wash buffer. These were purchased 
from BD Pharmingen Corp. 
(2) Enzyme-Linked Immunosorbent Assay (ELISA) Kits 
Human IFN-y ELISA kit was supplied by BD Pharmingen Corp which can detect 
an analytical range from 1 pg/ml to 300 pg/ml. 
2.1.10 Reagents and buffers for protein extractions 
(1) RIPA cell lysis buffer 
It was purchased from Assay Designs Inc, MI, USA and contains 50 mM 
Tris-HCl, pH 7.4’ 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2 mM sodium 
orthovanadate, 20 mM sodium pyrophosphate, 1 % Triton X-100, 1 % sodium 
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deoxycholate, 0.1 % SDS and 1 X protease inhibitors. The cell lysis buffer was used 
to extract total proteins for Western blot analysis and it was kept as 5 ml aliquots 
at-80^C. 
(2) NE-PERTM Nuclear and cytoplasmic extraction kits 
This was purchased from Pierce Biotechnology Inc, IL, USA. It supplied a 
complete set of cytoplasmic and nuclear extraction reagents that enabled the 
separation of non-denatured and active proteins of nuclear extract and cytoplasmic 
fraction from cultured cells and tissue. It contains cytoplasmic extraction reagent I 
(CER I) and cytoplasmic extraction reagent II (CER II) for lysing the cell membranes 
and release of cytoplasmic contents and nuclear extraction reagent (NER) for lysing 
the nuclei. It was stored at 4°C and used to extract nuclear protein for N F - K B activity 
assay. 
2.1.11 Reagents and buffers for SDS-polyacrylamide gel electrophoresis 
(PAGE) 
(1) 30 % (w/v) acrylamide solution 
The 30 % acrylamide/Bis solution (29:1) was purchased from Bio-Rad 
Laboratories, CA, USA. It was protected from light and stored at 4°C. 
(2) 10 o/o (w/v) ammonium persulfate (APS) solution 
This was prepared by dissolving 0.5 g APS (Sigma Chemical Co) in 5 ml double 
distilled water. The solution was kept in 500 aliquots at -20°C until use. 
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(3) Tris-HCl buffer (pH 7.5) 
Tris[hydroxylmethyl] amino methane (Tris) from Sigma Chemical Co was 
prepared as 1 M stock solution in diethyl pyrocarbonate (DEPC)-treated double 
distilled water. The buffer was adjusted to pH 7.5 with hydrochloric acid (HCl), 
autoclaved and stored at 4�C. 
(4) Upper buffer for stacking gel and lower buffer for separating gel 
The upper buffer was a 0.5 M Tris-HCl buffer adjusted to pH 6.8 and the lower 
buffer was a 1.5 M Tris-HCl buffer adjusted to pH 8.8. Both buffers were kept at 4°C. 
(5) 10 % sodium dodecyl sulfate (SDS) solution 
This was prepared by dissolving 10 g SDS (Sigma Chemical Co) in 100 ml 
double distilled water and kept at room temperature. 
(6) N,N,N',N'-Tetra-methylethylenediamine (TEMED) 
TEMED purchased from Sigma Chemical Co, was used to initiate the 
polymerization of SDS-polyacrylamide gel. It was stored at 4°C in dark. 
(7) Tris-Glycine-SDS electrophoresis buffer (10 X) 
Tris-glycine-SDS electrophoresis buffer 10 X concentrate containing 0.25 M 
Tris-HCl, pH 7.5, 1.92 M glycine and 1 % SDS in double distilled water was filtered 
by a 0.2 jim millipore filter and stored at 4°C. This concentrate was diluted fresh to 1 
X working buffer solution for SDS-PAGE. 
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(8) Laemmli sample buffer 
Laemmli sample buffer from Bio-Rad, contained 62.5 mM Tris-HCl, pH 6.8, 25 
% glycerol, 2 % SDS and 0.01 % bromophenol blue. Before use, 50 |LII of 2-ME was 
added to 950 |il of sample buffer for a final concentration of 5 % 2-ME, 710 mM. One 
part of sample was diluted with two parts of sample buffer. 
(9) Prestained SDS-PAGE standards 
The prestained SDS-PAGE standards (Bio-Rad Laboratories) contained a blue 
dye attached to standard proteins including phosphorylase B (104 kDa), bovine serum 
albumin (81 kDa), ovalbumin (47.7 kDa), carbonic anhydrase (34.6 kDa), soybean 
trypsin inhibitor (28.3 kDa) and lysozyme (19.2 kDa). The standard proteins (total 
625 ^ig) were prepared in 33 % (v/v) glycerol, 3 % SDS, 10 mM Tris (pH 7.0)，10 
mM DTT, 2 mM EDTA, 0.01 % NaNs, and stored at -20°C. 
2.1.12 Reagents and buffers for Western blot analysis 
(1) Antibodies 
Rabbit anti-total p38 MAPK, ERK, JNK and actin polyclonal antibodies were 
supplied from Santa Cruz Biotechnology Inc, CA, USA. Mouse anti-phospho-p38 
MAPK, ERK and JNK monoclonal antibodies were supplied by BD Pharmingen Corp. 
Mouse anti-IL-25R (IL-l7Rhl) monoclonal antibody was supplied from R&D 
Systems. Horseradish peroxidase conjugated donkey anti-rabbit and anti-mouse Ig 
secondary antibodies were purchased from Amersham Pharmacia Biotech Ltd. 
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(2) PVDF Western blotting membranes 
The microporous polyvinylidene difluoride (PVDF) membrane (pore size: 0.45 
|Lim) purchased from Amersham Pharmacia Biotech Ltd was stored at room 
temperature. 
(3) Tris-glycine buffer (10 X) 
Tris-glycine buffer 10 X concentrate consisting of 0.25 M Tris-HCl, pH 7.5 and 
1.92 M glycine in double distilled water was filtered by a 0.2 |im millipore filter and 
stored at 4°C. 
(4) Tris-glycine-methanol transfer buffer (1 X) 
The transfer buffer was prepared by mixing 20 % methanol in 1 X Tris-glycine 
buffer, and was kept at 4°C. 
(5) Tris-buffered saline Tween 20 (TEST) washing buffer 
This consisted of 10 mM Tris-HCl (pH 7.4)，150 mM sodium chloride and 0.05 
% (w/v) Tween 20 (Sigma Chemical Co). The solution was kept at 4°C. 
(6) 5 % Non-fat milk solution (blocking solution) 
Five grams of non-fat milk powder (San Hua Co, Hong Kong) was freshly 
dissolved in 100 ml TBST washing buffer. The solution was used as a blocking 
solution. 
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(7) Enhanced chemiluminescence (ECL) Western blotting analysis system 
It was a Western blotting detection kit purchased from Amersham Pharmacia 
Biotech Ltd. The kit contained a detection reagent 1 (62.5 ml), detection reagent 2 
(62.5 ml), anti-mouse Ig secondary antibody (horseradish peroxidase-1 inked whole 
antibody from sheep, 100 |al), anti-rabbit Ig secondary antibody (horseradish 
peroxidase-linked whole antibody from donkey, 100 |il), and 5g blocking reagent. The 
kit was used for the detection of either mouse or rabbit membrane bound primary 
antibodies and stored at 4°C. 
(8) ECL films (Hyperfilm 丁^  ECL ™) 
The Hyperfilm ™ ECL ™ was a high performance chemiluminescence film used 
for Western blot analysis. It was purchased from Amersham Pharmacia Biotech Ltd. 
2.1.13 Reagents and Buffers for Non-radioactive Electromobility Shift Assay 
(EMSA) 
(1) Tris-Borate-EDTA (TBE) Electrophoresis Buffer (5 X) 
The 5 X TBE electrophoresis buffer stock was prepared by dissolving 54 g Tris, 
27.5 g boric acid and 20 ml 0.5 M EDTA in 1 L double distilled water. The pH of the 
buffer was adjusted to 8.0. A 0.5 X working TBE buffer was prepared by diluting one 
part of the 5 X stock TBE buffer with nine parts of double distilled water. Both of the 
working and stock solutions were kept at 4°C. 
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(2) Hybond-N+ Nylon Membrane 
The nylon membrane purchased from Amersham is positively charged and has a 
binding capacity for nucleic acids up to 600 |ag/cm^. 
(3 ) N F - K B Oligonucleotide 
The oligonucleotide (Promega), containing NF-KB D N A binding site, was 
supplied in TE buffer at a concentration of 1.75 pmol/ml. It was stored at -20�C and 
has the following sequence: 5' -AGT TGA GGG GAC TTT CCC AGG C-3' 
5’ -TCAACT CCC CTG AAA GGG TCC G-3' 
(4 ) Biotinylated N F - K B Oligonucleotide 
Biotin 3'-conjugated NF-KB oligonucleotide was purchased from Research 
Genetics, Gibco. The lyophilized oligos were reconstituted in DEPC-treated water to 
obtain a concentration of 100 pmole/)Lil. The oligos were diluted with annealing buffer 
at 65"C and annealed at room temperature. The annealed double-stranded oligos were 
stored at -20°C and used for detection of transcription factor/DNA binding. 
(5) LightShiftTM chemiluminescent EMSA Kit 
The EMSA kit, purchased from Pierce, consisted of two sets of components. The 
first set contained a 10 X binding buffer (100 mM Tris, 500 mM KCl, 10 mM DTT, 
pH 7.5), biotin-EBNA control DNA, unlabeled EBNA DNA, EBNA extract for 
positive control, poly (dl dC), 50 % glycerol, 1 % NP-40, 1 M KCl, 100 mM MgCb, 
200 mM EDTA pH 8，and 5 X loading buffer for DNA/protein binding reaction. The 
second set contained a streptavidin-horseradish peroxidase conjugate, 
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chemiluminescent substrate, luminal/enhancer solution, blocking buffer, 4 X wash 
buffer and a substrate equilibration buffer for signal detection. 
2.1.14 Reagents and buffers for cell viability and proliferation assay 
(1) Thiazolyl blue tetrazolium bromide (MTT) 
It was purchased from Sigma-Aldrich Inc, MD, USA. MTT was dissolved in 
PBS to 5 mg/ml and stored at 4°C. 
(2) Cell proliferation ELISA, 5-bromo-2'-deoxyuridine (BrdU) (colorimetric) 
The kit was purchased from Roche Diagnostics GmbH, Penzerg, Germany. It is a 
colorimetric immunoassay for the quantification of cell proliferation based on the 
measurement of BrdU incorporation during DNA synthesis. It consists of BrdU in 
PBS (10 mM, pH 7.4)，fixing and denaturing solution, anti-BrdU monoclonal 
antibody conjugated with peroxidase, antibody dilution solution, washing buffer and 
substrate solution. 
2.1.15 Reagent kit for endotoxin level assay 
QCL-1000 ® Chromogenic Limulus Amebocyte Lysate (LAL) Test was 
purchased from Cambrex Bio Science Walkersville Inc. The kit contains the LAL 
prepared from the circulating amebocytes of the horseshoe crab Limidus polyphcmus, 
E. coli endotoxin and chromogenic substrate. 
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2.1.16 Other Reagent Kits 
(1) Fluorescent enzyme immunoassay (FEIA) of allergen-specific IgE 
antibodies 
Pharmacia CAP System™ Radioallergosorbent Test (RAST) FEIA kit was 
purchased from Pharmacia Diagnostics AB, Uppsala, Sweden. It was used to measure 
the concentrations of plasma allergen-specific IgE antibodies. The measuring range 
was 0.35 - 100 klU/L for undiluted serum or plasma and the detection limit was 
below 0.35 klU/L. The CV of intra-assay and inter-assay precisions were 7.7 % and 
7.3 % respectively. 
(2) Micro BCA Protein Assay Kit 
The kit was purchased from Pierce Chemical Co, IL, USA and used to 
determined the concentration of proteins in EMSA and Western blot analysis. 
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2.2 Methods 
2.2.1 Purification of human Th lymphocytes and cell culture 
Fresh human buffy coat was firstly diluted 1:2 with 1 X PBS. It was then loaded 
onto same volume of Ficoll-Paque solution in a 50 ml centrifuge tube, followed by 
centrifugation at 4®C, 1,800 rpm for 30 min. The PBMC fraction was collected and 
washed twice with 0.5 X PBS. The PBMC was then incubated with a cocktail of 
biotin-conjugated antibodies which act against non-CD4+ cells at 4°C for 10 min. 
After that, the mixture was incubated with anti-biotin magnetic microbeads for a 
further 15 min. Finally, the cells were washed with 1 X PBS supplemented with 2 % 
FCS and added onto a LS column placed in magnetic field. The fraction collected 
contained Th cells with a purity of at least 95 % as assessed by immunofluorescent 
staining using CD4 antibody. Purified Th cells were cultured in RPMI 1640 medium 
supplemented with 10 % FCS and kept under a humidified atmosphere with 5 % CO2 
at 37°C. 
2.2.2 Measurement of Total and Allergen-specific IgE Concentrations 
Total IgE concentration in plasma was measured by microparticle immunoassay 
(IMx analyzer; Abbott Laboratories, Abbott Park, IL, USA) and analysed as a 
quantitative trait following logarithmic transformation (IgEiog). Specific IgE 
antibodies to food mix, house dust mite, cat, dog, cockroach and mould mix were 
measured by fluorescent enzyme immunoassay (AutoCAP system, Pharmacia 
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Diagnostics), using Pharmacia CAP System^'^ RAST FEIA kit, according to the 
manufacturer's instruction. The grading of specific IgE into RAST classes 1 to 6 was 
made according to manufacturer's instruction, with specific IgE concentration > 0.35 
klU/L being positive. Subjects were defined as atopic if they had at least one positive 
result on testing for allergen-specific IgE. 
2.2.3 Immunophenotyping of cells by flow cytometry 
Th cells (5 X 10^ cells/0.5ml) after preceding treatment were harvested and 
resuspended with cold FACS medium. After blocking with 2 % human pooled serum 
for 20 min at 4°C and washed with FACS medium, cells were incubated either with 
fluorescein-conjugated mouse anti-human mAb antibody or fluoresce in-conjugated 
mouse IgGi and IgG2a isotype for 30 min at 4 � C in dark. After washing, cells were 
finally resuspended in 1 % paraformaldehyde in 1 X PBS as fixative. The expression 
of cell surface markers was then analyzed by flow cytometry in terms of mean 
fluorescence intensity (MFI). 
2.2.4 Protein array of human cytokines and chemokines 
Th cells (1 X 10^ cells/ml) were treated for 72 h and the protein expression 
profile of cytokines and chemokines in culture supernatant were assessed by RayBio 
human cytokine array V. The cytokine array membranes were firstly blocked for 30 
min and then incubated with 1 ml culture supernatant for 2 h at room temperature. 
After washing, the membranes were incubated with biotin-conjugated antibodies for 2 
h. The membranes, after washing for the second time, were incubated with 
4 2 
Chapter 2 Materials and Methods 
HRP-conjugated streptavidin for a further 2 h. Finally, antibody-antigen complexes 
were then detected using ECL chemiluminescent detection system according to the 
manufacturer's instructions (Amersham and Pharmacia Biotech Corp). The relative 
band intensity was analyzed by Bio-Rad Quantity™ One (Bio-Rad Laboratories). 
2.2.5 Quantitative analysis of cytokines and chemokines by flow cytometry 
Th cells (1 X 10^ cells/ml) were treated for 72 h and the concentrations of 
cytokines and chemokines in culture supernatant were measured by cytometric bead 
array (CBA) (BD Pharmingen Corp) using a FACSCalibur flow cytometer (Becton 
Dickinson, CA, USA). The kits contained bead populations with distinct fluorescence 
intensities and they have been coated with capture antibodies specific for different 
cytokines and chemokines. The bead populations could be resolved in the FL3 
channel of flow cytometer. First, 50 |xl plasma or culture supernatants were incubated 
with 50 i-il different capture beads mixtures and 50 )il PE-conjugated detection 
antibodies. The mixture formed a sandwich complex and after 3 h incubation, the 
capture beads were washed and re-suspended for sample data acquisition using Cell 
Quest (FACSCalibur). The sample results were finally generated in graphical format 
using the BD CBA analysis software. 
2.2.6 Quantitative analysis of IFN-y by ELISA 
Concentration of human IFN-y in the culture supernatants was measured using 
the corresponding ELISA kit (BD Pharmingen Corp) according to manufacturer's 
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instruction. Enzymatic products were measured at 450 nm corrected by the reading at 
570 nm using Victor Multilabel Counter (PerkinElmer, MA, USA) 
2.2.7 SDS-PAGE 
A Bio-Rad Mini-PROTEAN apparatus was used for discontinuous 
polyacrylamide gel electrophoresis. The recipe of the stacking gel was 0.187 M 
Tris.HCl, pH 6.8’ 5 % acrylamide, 0.1 % SDS, 0.1 % APS, 0.1 % TEMED, while the 
lower separating gel was 0.375 M Tris.HCl, pH 8.8’ 12.5 % acrylamide, 0.1 % SDS, 
O.I % APS, 0.075 % TEMED. The separating gel solution mixed as the above recipe 
was casted into the vertical gel glass plates of sizes [Inner: 7.3 x 10.2 x 0.1 cm; Outer: 
8.3 X 10.2 X 0.1 cm (h x w x d)]. A layer of 0.1 % SDS was laid on the top to assist 
the formation of a straight line interphase. After the separating gel was set, the 5 % 
polyacrylamide stacking gel was set with a comb to form ten wells of sizes 1.5 x 0.5 x 
0.1 cm (h X w X d). Electrophoresis was carried out using Tris-Glycine-SDS Running 
Buffer at a constant voltage of 100 V for about 100 - 120 min. After electrophoresis, 
the gel was either used for immunoblotting or stained with Coomassie blue brilliant 
dye (0.2 % R 250 Coomassie brilliant blue, 50 % methanol, 10 % acetic acid) for 1 h 
and de-stained with a solution of 5 % methanol and 10 % acetic acid at room 
temperature. 
2.2.8 Western blot analysis 
An equal amount of proteins was subjected to 10 % SDS-PAGE before blotting 
onto a PVDF membrane (Amersham and pharmacia Biotech Corp). The membrane 
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was blocked with 5 % skimmed milk in Tris-buffered saline with 0.05 % Tween 20, 
pH 7.6 for 1 h at room temperature, and probed with primary rabbit or mouse 
anti-human antibody at 4°C overnight. After washing, membranes were incubated 
with secondary donkey anti-rabbit or mouse antibody coupled to horseradish 
peroxidase (Amersham and Pharmacia Biotech Corp) for 1 h at room temperature. 
Antibody-antigen complexes were then detected using ECL chemiluminescent 
detection system according to the manufacturer's instructions (Amersham and 
Pharmacia Biotech Corp). The relative band intensity was analyzed by Bio-Rad 
Quantity™ One (Bio-Rad Laboratories). 
2.2.9 Non-radioactive Electromobility Shift Assay (EMSA) / Gel Shift Assay 
After Th cells (1 x 10') were harvested and washed, nuclear proteins were 
extracted with NE-PER™ nuclear and cytoplasmic extraction reagents (Pierce) 
according to the manufacturer's instructions. Equal amounts of nuclear extracts were 
subjected to a test for N F - K B protein/DNA binding using LightShift™ 
chemiluminescent EMSA kit (Pierce Chemical Co.) with a biotin end-labeled p50 
N F - K B oligonucleotide (5'-AGT TGA GGG GAC TTT CCC AGG C-3') (Research 
Genetics). Briefly, nuclear extracts with same protein amount were incubated with 
biotin end-labeled N F - K B oligonucleotide for 2 0 min at room temperature to allow 
DNA/protein binding. The DNA/protein complexes were then resolved by a 6 % 
native polyaery 1 amide gel electrophoresis and transferred to a Hybond-N+ membrane 
(Amersham and Pharmacia Biotech). The biotin end-labeled DNA was detected using 
a streptavidin-horseradish peroxidase conjugate and a chemiluminescent substrate 
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according to the manufacturer's instructions. The relative band intensity was analyzed 
by Bio-Rad Quantity™ One (Bio-Rad Laboratories). 
2.2.10 MTT assay 
Th cells (2 X 10^ cells/0.2ml) were inoculated into a 96-well plate. Various 
inhibitors at serial concentrations were added to the cells. After 36-h incubation, MTT 
(50 昭）(Sigma Chemical Co) was added to each well and incubated for 12 h. Viable 
cells Liptook MTT and reduced it into dark blue water-insoluble formazan by 
mitochondrial dehydrogenase which reflected the normal function of mitochondria and 
cell viability. The cells were then iysed with DMSO (200 |il) to yield the colour 
solution. The absorbance at OD550 nm was measured by ELISA plate reader to 
quantify the viable cells. 
2.2.11 Cell proliferation assay 
The cell proliferation rate was assayed with the colorimetric BrdU ELISA 
(Roche Diagnostics Corp). Th cells (2 x 10^  cells/0.2ml) were inoculated into a 
96-well plate. Various stimulators at serial concentrations were added to the cells for 
72 h. BrdU was then added and incubated with the cells for 4 h. BrdU was 
incorportated in place of thymidine into the DNA of proliferating cells. By adding the 
anti-BrdU conjugated with peroxidase and substrate tetramethy-benzidine, the color 
developed thereby directly correlated to the number of proliferating cells. The 
absorbance at OD450 nm was measured by ELISA plate reader. 
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2.2.12 Endotoxin level assay 
The endotoxin level was assayed by the Chromogenic Limulus Amebocyte 
Lysate (LAL) Test. Samples in serial concentrations were added to 96-well plate and 
mixed with the LAL for 10 min at 37°C . The substrate solution was then mixed with 
the LAL-samples and incubated at 37°C for an additional 6 min before stopping by 
stop reagent. In this process, Gram-negative bacterial endotoxin catalyzed the 
activation of a proenzyme in the LAL. The activated enzyme then catalyzed the 
splitting of pNA from the colourless substrate Ac-lle-Glu-Ala-Arg-pNA. The yellow 
coloured-pNA could be measured photometrically at OD450 nm by ELISA plate 
reader after the reaction was stopped. 
2.2.13 Statistical analysis 
Data in figures were presented either as mean 士 SEM in histograms or curves. 
Differences between groups were assessed by the unpaired Student t test. A 
probability p < 0.05 was considered significantly different. All analyses were 
performed using the Statistical software Graph Pad Prism (GraphPad Prism for 
Windows, version 3.00，GraphPad Software Inc, CA, USA). 
4 7 
Chapter 3 Results 
Chapter 3 
Results 
3.1 Effects of IL-18 and IL-25 on the induction of Thl/2 cytokine and 
chemokine release from costimulated Th lymphocytes 
3.1.1 IL-18 and IL-25 could up-regulate the protein expression of cytokines and 
chemokines 
Protein array was used to screen the effect of pro-inflammatory cytokine IL-18 
and Th2 cytokine IL-25 on cytokine induction from costimulated Th cells. Th cells 
costimulated with anti-CD3 and anti-CD28 antibodies were treated with or without 
IL-18 or IL-25 for 72 h. The optimal dose and incubation time of the above antibodies 
and cytokines had been determined previously for significant effect (data not shown). 
As shown in Figure 3.1，costimulated Th cells could release IL-5, IL-8, IL-10, etc. 
Moreover, IL-18 could further induce the release of Thl cytokines IFN-y, Th2 
cytokines including IL-5, IL-6 and also chemokines including RANTES and MIP-lp, 
whereas IL-25 could induce the release of IL-5, RANTES and MIP-lp together with 
costimulation. 
3.1.2 IL-18 but not IL-25 induced the release of IFN-y and TNF-a 
Figure 3.2 shows that costimulation could induce the release of Thl cytokines 
IFN-y and TNF-a from Th cells. However, IL-18 but not IL-25 could significantly 
augment the release of IFN-y and TNF-a from costimulated Th cells in a 
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dose-dependent manner (all p<0.01). IL-18 alone had no inductive effect. 
3.1.3 IL-18 and IL-25 induced the release of IL-5, IL-6 and IL-10 
Figure 3.3 shows that both IL-18 and IL-25 could significantly induce the release 
of Th2 cytokines IL-5, IL-6 and IL-10 from costimulated Th cells (all p<0.05). 
Furthermore, IL-18 or IL-25 alone was shown to significantly induce the release of 
IL-6 but not IL-5 and IL-10 in the absence of costimulation. 
3.1.4 IL-18 induced the release of IP-10, MIG, RANTES, MlP-la and IL-8 
As shown in Figure 3.4, IL-18 could significantly induce IP-10, MIG, RANTES, 
MlP- la and IL-8 from costimulated Th cells (all p<0.05). IL-18 alone had no 
inductive effect. 
3.1.5 IL-25 induced the release of IP-10, MIG and RANTES 
Figure 3.4 shows that IL-25 could only induce IP-10, MIG and RANTES from 
costimulated Th cells significantly (all p<0.05). IL-25 alone had no inductive effect. 
3.1.6 IL-18 and IL-25 did not enhance the proliferation of costimulated Th cells 
BrdU proliferation assay was performed to ensure the induced release of Thl/2 
cytokines and chemokines was not due to an increase in cell number under the effect 
of IL-18 and IL-25. As shown in figure 3.5, IL-18 and IL-25 had no significant effect 
on cell proliferation when compared to CD3+28 treatment. 
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Figure 3.1 Representative profile of cytokine release from costimulated Th cells 
treated with IL-18 or IL-25. Th cells (1 x 10^ cells/ml) costimulated with anti-CD3 
and anti-CD28 antibodies (both 1 jig/ml) were treated together with or without IL-18 
(25 ng/ml) or IL-25 (25 ng/ml) for 72 h. Cell-free culture supernatant was then 
harvested and 79 different cytokines in culture supernatant were detected using 
antibody-based Raybio human cytokine array V. Positive and negative controls were 
designed at (lA, IB, IC, ID, 8J, 8K) and (IE, IF, 81) respectively. Triplicate 
experiments were performed with essentially identical results. Table listed the format 
of antibodies on the cytokine membrane array. 
Abbreviation: C0= CD3+28 
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Figure 3.2 Effects of (a) IL-18 and (b) IL-25 on the release of Thl cytokines from 
Th cells. Th cells (1 x 10^ cells/ml) costimulated with anti-CD3 and anti-CD28 
antibodies (both 1 |ig/ml) were treated together with or without an increasing dose of 
IL-18 or IL-25 for 72 h in a 24-well plate. IFN-y and TNF-a released into the culture 
supernatant were determined by ELISA and CBA kit using flow cytometry 
respectively. Results are expressed as the arithmetic mean plus SEM from five 
independent experiments. Student's t test was used to assess the difference between all 
treatment groups (*p<0.05, **p<0.01 and ***p<0.001 when compared to CD3+28). 
Abbreviation: CO= CD3+28 
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Figure 3.3 Effects of (a) IL-18 and (b) IL-25 on the release of Th2 cytokines from 
Th cells. Th cells (1 x 10^ cells/ml) costimulated with anti-CD3 and anti-CD28 
antibodies (both 1 |_ig/ml) were treated together with or without an increasing dose of 
IL-18 or IL-25 for 72 h in a 24-well plate. IL-5, IL-6 and IL-10 released into the 
culture supernatant were determined by CBA kit using flow cytometry. Results are 
expressed as the arithmetic mean plus SEM from five independent experiments. 
Student's t test was used to assess the difference between ail treatment groups 
(*p<0.05, •*p<0.01 and ***p<0.001 when compared to CD3+28). 
Abbreviation: CO= CD3+28 
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Figure 3.4 Effects of (a) IL-18 and (b) IL-25 on the release of chemokines from 
Th cells. Th cells (1 x 10^  cells/ml) costimulated with anti-CD3 and anti-CD28 
antibodies (both l|j.g/ml) were treated together with or without an increasing dose of 
IL-18 or IL-25 for 72 h in a 24-well plate. IP-10, MIG, RANTES, MlP-la and IL-8 
released into the culture supernatant were determined by CBA kit using flow 
cytometry. Results are expressed as the arithmetic mean plus SEM from five 
independent experiments. Student's t test was used to assess the difference between all 
treatment groups (*p<0.05, **p<0.01 and ***p<0.001 when compared to CD3+28). 
Abbreviation: C0= CD3+28 
56 
Chapter 3 Results 
•S 5 0 ] 
c Q. 4 0 - 丁 
1 1 1 m i l l 
/ / / / / / / / 
Figure 3.5 Effects of IL-18 and IL-25 on the proliferation rate of Th cells. Th cells 
(1 X 106cells/ml) costimulated with anti-CD3 and anti-CD28 antibodies (both 1 |.ig/ml) 
were treated together with or without an increasing dose of IL-18 or IL-25 for 72 h in 
a 96-well plate. The proliferation rate was measured by BrdU ELISA. Percentage 
increase in proliferation compared to control was calculated as absorbance value of 
treated cells / absorbance value of control cells x 100%. 
Abbreviation: CO= CD3+28 
5 7 
Chapter 3 Results 
3.2 Effects of IL-18 and IL-25 on the activation of p38 MAPK, ERK, JNK and 
NF-zcB 
In the previous part, IL-18 and IL-25 were found to induce significant amount of 
Thl /2 cytokines and chemokines from costimulated Th cells. We then moved on to 
study the activation of intracellular p38 MAPK, ERK, JNK and NF-/C B signaling 
pathways to elucidate their intracellular regulatory mechanisms. 
3.2.1 Costimulation with or without IL-18 and IL-25 could activate p38 MAPK, 
ERK and JNK 
Costimulation with or without IL-18 and IL-25 was shown to activate p38 
MAPK (Figure 3.6a)，ERK (Figure 3.6b) and JNK (Figure 3.6c). For ERK and JNK 
but not p38 MAPK, phosphorylation peaked at 5 min and sustained till 30 min. 
Treatment with IL-18 and IL-25 alone did not activate any pathways (data not 
shown). 
3.2.2 Costimulation with or without IL-18 and IL-25 could induce NF- n B activity 
As shown in Figure 3.7a and 3.7b, shifted bands were not observed in medium 
control, IL-18 and IL-25 treatment, indicating a low activity of NF- n B. However, 
costimulation with or without IL-18 and IL-25 could induce NF-zc B activity as 
shown by the shifted bands. The induced activity could be suppressed with 
BAY 117082. Negative control with labeled DNA probe only and competitive control 
with excess unlabeled NF- /c B DNA were used to confirm the specificity of the 
experiment. 
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Figure 3.6 Effects of IL-18 and IL-25 on the activation of (a) p38 MAPK, (b) 
ERK and (c) JNK in costimulated Th cells. Th cells (7 x 10^ ) costimulated with 
anti-CD3 and anti-CD28 antibodies (both 1 |ig/ml) were treated together with or 
without IL-18 (25 ng/ml) or IL-25 (25 ng/ml) for the indicated period of time. Total 
cellular proteins were extracted for the detection of signaling molecules by Western 
blot analysis. Triplicate experiments were performed with essentially identical results. 
Abbreviation: CO= CD3+28 
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Figure 3.7 Effects of IL-18 and IL-25 on the induction of NF-/cB activity in 
costimulated Th cells. Th cells (1 x were pretreated with or without BAY 117082 
(1 |iM) for 1 h followed by (a) costimulation by anti-CD3 and CD28 antibodies (both 
1 i^g/ml) and (b) stimulation with IL-18, IL-25 (both 25ng/ml) and CO+IL-18/ IL-25 
for further 14 h. Nuclear protein was extracted and 5 \ig was used for EMSA. 
Triplicate experiments were performed with essentially identical results. 
Abbreviations: CO= CD3+28 BAY=BAY117082 
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3.3 Effects of inhibitors on the IL-18 and IL-25-induced release of Thl/2 
cytokines and chemokines 
To confirm the intracellular regulatory mechanisms, BAYl 17082, SB203580, 
SP600125 and PD098059, the selective inhibitors of NF-KB, p38 MAPK, JNK and 
ERK pathways respectively, were used to confirm the regulatory mechanisms. 
3.3.1 Optimal dosage of SB203580, PD98035, SP600125 and BAY 117082 
The cytotoxicity of different inhibitors was firstly determined by MTT assay. 
Figure 3.8 shows that the pre-optimized doses from previous study of 5, 5, 2.5 and 1 
^iM for SB203580, PD98035, SP600125 and BAY 117082 respectively did not cause 
any cytotoxic effect on cell viability. DMSO was used as vehicle for the above 
inhibitors and it did not have any cytotoxic effect on Th cells. 
3.3.2 SB203580, PD98035 and BAY 117082 but not SP600125 suppressed the IL-18 
and IL-25-induced release ofThl /Th2 cytokines 
As shown in Figure 3.9，SB203580, PD98035 and BAY 117082 but not 
SP600125 could significantly suppress the IL-18-induced release of Thl cytokines 
IFN-y, TNF-a and Th2 cytokines IL-5, IL-6 and IL-10 (all p<0.05) from costimulated 
Th cells. Figure 3.10 shows that the same result was observed in IL-25-induced IL-5 
and IL-10 but not IL-6 which was suppressed by PD98035 and BAY 17082 only. 
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3.3.3 SP600125 suppressed the IL-18 and IL-25-induced release of chemokines 
Figure 3 .11 and 3 . 1 2 show that only SP600125 but not the MAPKs and NF-KB 
inhibitors could significantly suppress the IL-18 and IL-25-induced release of IP-10, 
MIG and RANTES from costimulated Th cells. IL-18-induced MlP-la could only be 
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Figure 3.8 Effects of SB203580, PD98035, SP600125 and BAY117082 on the 
viability of Th cells. Th cells were incubated with (a) SB203580, PD98035, 
SP600125, BAY 117082 and (b) DMSO for 72 h and the viability was assessed by 
MTT assay. DMSO was used as vehicle for the above inhibitors. Results are 
expressed as the arithmetic mean plus SEM from four independent experiments. 
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Figure 3.9 Effects of SB203580, PD98035, SP600125 and BAY117082 on the 
IL-18-induced (a) Thl and (b) Th2 cytokines in costimulated Th cells. Th cells (1 
X 10^ cells/ml) were pretreated with or without SB203580 (5 JUM), PD98035 (5 ^M), 
SP600I25 (2.5 nM) or BAY 117082 (1 ^iM) for 1 h followed by stimulation with or 
without IL-18 (25ng/ml) in the presence of anti-CD3 and anti-CD28 antibodies (both 
l|ig/ml) for 72 h. The cytokine expression was detected using cytometric bead array 
and ELISA. Results are expressed as the arithmetic mean plus SEM from four 
independent experiments. Student's t test was used to assess the difference between all 
treatment groups (*p<0.05，**p<0.01 and *"p<0.001 when compared to CD3+28; 
#p<0.05，##p<0.01 and ###p<0.001 when compared to C0+IL18). 
Abbreviations: CO=CD3+28 SB=SB203580 PD=PD98053 SP=SP600125 
BAY=BAY117082 
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Figure 3.10 Effects of SB203580, PD98035, SP600125 and BAY117082 on the 
IL-25-induced Th2 cytokines in costimulated Th cells. Th cells (1 x 10^ cells/ml) 
were pretreated with or without SB203580 (5 |iM), PD98035 (5 ^M), SP600125 (2.5 
^iM) or BAY 117082 (1 ^iM) for 1 h followed by stimulation with or without IL-25 
(25ng/ml) in the presence of anti-CD3 and anti-CD28 antibodies (both Ijiig/ml) for 72 
h. The cytokine expression was detected using cytometric bead array. Results are 
expressed as the arithmetic mean plus SEM from four independent experiments. 
Student's t test was used to assess the difference between all treatment groups 
('p<0.05, " p O . O l and …pO.OOl when compared to CD3+28; #p<0.05’ ##p<0.01 and 
###p<0.001 when compared to CO+IL25). 
Abbreviations: CO=CD3+28 SB=SB203580 PD=PD98053 SP=SP600125 
BAY=BAY117082 
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Figure 3.11 Effects of SB203580, PD98035, SP600125 and BAY117082 on the 
IL-18-induced chemokines in costimulated Th cells. Th cells (1 x 106 cells/ml) 
were pretreated with or without SB203580 (5 |iM), PD98035 (5 ^iM), SP600125 (2.5 
|iM) or BAY 117082 (1 ^iM) for 1 h followed by stimulation with or without IL-18 
(25ng/ml) in the presence of anti-CD3 and anti-CD28 antibodies (both l|ig/ml) for 72 
h. The chemokine expression was detected using cytometric bead array. Results are 
expressed as the arithmetic mean plus SEM from four independent experiments. 
Student's t test was used to assess the difference between all treatment groups. 
(•p<0.05, "p<0.01 and …p<0.001 when compared to CD3+28; #p<0.05’ ##p<0.01 and 
綱pO.OOl when compared to C0+IL18). 
Abbreviations: CO=CD3+28 SB=SB203580 PD=PD98053 SP=SP600125 
BAY=BAY117082 
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Figure 3.12 Effects of SB203580, PD98035, SP600125 and BAY117082 on the 
IL-25-induced chemokines in costimulated Th cells. Th cells (1 x 10^ cells/ml) 
were pretreated with or without SB203580 (5 |LIM), PD98035 (5 |LIM), S P 6 0 0 1 2 5 (2.5 
^iM) or BAY 117082 (1 ^iM) for 1 h followed by stimulation with or without IL-25 
(25ng/ml) in the presence of anti-CD3 and anti-CD28 antibodies (both 1 |ig/ml) for 72 
h. The chemokine expression was detected using cytometric bead array. Results are 
expressed as the arithmetic mean plus SEM from four independent experiments. 
Student's t test was used to assess the difference between all treatment groups. 
(*p<0.05, " p O . O l and …pO.OOl when compared to CD3+28; #p<0.05，##p<0.01 and 
###p<0.001 when compared to CO+IL25). 
Abbreviations: CO=CD3+28 SB=SB203580 PD=PD98053 SP=SP600125 
BAY=BAY117082 
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3.4 Effects of inhibitors on the cell surface expression of IL-18 and IL-25 
receptors 
To further investigate the molecular mechanisms of IL-18 and IL-25-induced 
effects on costimulated Th cells, we studied the surface expression of IL-18 and IL-25 
receptors on costimulated Th cells after treatment with BAY 117082, SB203580, 
SP600125 and PD098059, the selective inhibitors of NF-KB , p38 M A P K , JNK and 
ERK pathways respectively. 
3.4.1 SB203580, PD098059 and BAY 117082 but not SP600125 could suppress 
IL-18 receptor on costimulated Th cells 
Figure 3.13 shows that cell surface IL-18 receptor on Th cells was significantly 
up-regulated by costimulation. Moreover, the induced expression was shown to be 
suppressed by SB203580, PD098059 and BAY 117082 but not SP600125. 
3.4.2 SB203580, SP600125, PD098059 and BAY 117082 could not suppress IL-25 
receptor on costimulated Th cells 
As shown in figure 3.14，cell surface IL-25 receptor on Th cells was found to be 
up-regulated by costimulation. However, treatment with SB203580, SP600125, 
PD098059 and BAY 117082 could not suppress the induced expression. 
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Figure 3.13 Effects of SB203580, PD098059, BAY117082 and SP600125 on IL-18 
receptor a on costimulated Th cells. Th cells (1 x 10^cells/ml) were pretreated with 
or without SB203580 (5 ^iM), PD98035 (5 ^iM), SP600125 (2.5 \iM) or BAY 117082 
(1 fiM) for 1 h followed by costimulation with anti-CD3 and anti-CD28 antibodies 
(both l|Lig/ml) for further 72 h. The IL-18R expression was detected by flow 
cytometry using mAb IgGi isotype control and mAb against IL-18R. Results are 
expressed as the arithmetic mean plus SEM from four independent experiments. 
Student's t test was used to assess the difference between all treatment groups 
(*p<0.05, **p<0.01 when compared to CD3+28). 
Abbreviations: CO=CD3+28 SB=SB203580 PD=PD98053 SP=SP600125 
BAY=BAYJI7082 
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Figure 3.14 Effects of SB203580, PD098059, BAY117082 and SP600125 on 
IL-17Rhl on costimulated Th cells. Th cells (7 x 10^  cells/ml) were treated with or 
without SB203580 (5 ^iM), PD98035 (5 \iM), SP600125 (2.5 \iM) or BAY 117082 
(l^iM) for 1 h followed by costimulation with anti-CD3 and anti-CD28 antibodies 
(both l |ig/ml) for further 72 h. Total cellular proteins were extracted for the detection 
of IL-I7Rhl by Western blot analysis. Triplicate experiments were performed with 
essentially identical results. 
Abbreviations: CO=CD3+28 SB=SB203580 PD=PD98053 SP=SP600125 
BAY=BAY117082 
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3.5 Effects of costimulation on the expression of cell surface markers on Th 
lymphocytes 
In this part, we investigate the effect of costimulation on the cell surface 
expression of adhesion molecules like LFA-1 and ICAM-1, cytokine and chemokine 
receptors such as IL-2R, CCR5, CXCR3, and also costimulatory molecules including 
ICOS and CTLA-4. As shown in Figure 3.15, the expression of all the surface 
markers detected was increased except CCR5 after costimulation when compared to 
control. However, in the presence of costimulation, IL-18 and IL-25 could not further 
enhance the expression of the above markers. 
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Figure 3.15 Effects of costimulation on the surface expression of (a) LFA-1, (b) 
ICAM-1, (c) CCR5，(d) CXCR3, (e) ICOS, (f) CTLA-4, (g) IL-2R on Th cells. Th 
cells (1 X 10^ cells/ml) were costimulated with anti-CD3 and anti-CD28 antibodies 
(both 1 i^g/ml) for 72 h. Expression of surface markers was detected by flow 
cytometry using their corresponding isotype control and mAb. Data are presented as 
histograms of relative cell counts with fluorescence intensity. Each histogram 
represents 5 x 1 0 ^ cells. These are representative figures from 4 independent 
experiments with very similar results. Vertical bar indicates cutoff for peak of mAb 
staining with control medium. Unbold and bold lines represent isotype control-treated 
and mAb-treated cells respectively. 
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Chapter 4 
Discussion 
4.1 Effects of IL-18 and IL-25 on the release of Thl/2 cytokines and chemokines 
As mentioned in 1.6，patients of bronchial asthma are characterized by 
co-presence of Thl and Th2 cells, increased eosinophil and neutrophil numbers and 
elevated IL-18, IL-25, IFN-y, IL-5, IL-6 and IL-8 levels [Humbles et al, 2004; Wong 
et al, 2001, 2005; Cembrzynska-Nowak et al, 1993; Ordonez et al, 2000]. By studying 
the intracellular signaling mechanisms of IL-18/25-induced release of cytokines and 
chemokines from Th cells upon costimulation, it can facilitate our understanding of 
the pathogenesis of bronchial asthma. 
The present results of cytokine array analysis (Figure 3.1) in conjunction with 
those of bead-based multiplex assay (Figure 3.2-3.4) confirmed that IL-18 could 
selectively induce the significant in vitro release from costimulated Th cells of Thl 
cytokines IFN-y and TNF-a, Th2 cytokines IL-5, IL-6 and IL-10, and chemokines 
IP-10, MIQ RANTES, MlP- la and IL-8 (all p < 0.05). IL-25 could only induce the 
significant release of Th2 cytokines IL-5, IL-6, IL-10, and chemokines IP-10, MIG 
and RANTES (all p < 0.05). Moreover, the magnitude of the induction of chemokines 
by IL-25 was also less than that of IL-18, if there was any. Without costimulation, 
IL-18 and IL-25 alone could only induce very little amount, if there was any, of 
cytokines and chemokines. Our above results therefore are not only compatible with 
previous study [Hata et al, 2004], but also characterize the induced cytokine and 
chemokine profiles from IL-18 and IL-25 activated Th cells upon costimulation. As 
also observed by us, there was no significant difference of induced cytokine and 
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chemokine profiles from costimulated Th cells between atopic and non-atopic 
subjects (all p > 0.05). Since costimulation with or without IL-18 and IL-25 for 72 h 
exhibited only about 30 - 40 % increase in proliferation of Th cells, the release of 
cytokines and chemokines was not due to the cell proliferation. 
It is interesting to observe that IL-18 and IL-25 could markedly induce the 
release of cytokines and chemokines from Th cells upon costimulation but not when 
IL-18 or IL-25 was added alone. One assumption is that unstimulated Th cells express 
low levels of IL-18 and IL-25 receptors. To confirm the hypothesis, the expression of 
IL-18R and IL-25R was studied by flow cytometry and Western blot respectively. We 
demonstrated that upon costimulation, IL-18R and IL-25R were markedly 
up-regulated (Figures 3.13 and 3.14). Therefore, the activation of costimulated Th 
cells by IL-18 and IL-25 follows chronological events. 
The effects of IL-18 and IL-25 suggest that these two cytokines play crucial roles 
in eliciting the functions of Th cells. In addition to stimulating the release of cytokines 
and chemokines, IL-18 has been shown to stimulate the proliferation of activated T 
cells [Dinarello, 1999], and enhancement of Fas ligand expression in NK and 
cytotoxic T lymphocytes [Dao et al, 1996]. Since IL-25 is a Th2 cytokine, it is 
reasonable that it can only induce Th2 cytokines IL-5, IL-6 and IL-10 but not Thl 
cytokines as demonstrated in our study. Intranasal administration of IL-25 has been 
shown to induce the production of Th2 cytokines and the expression of chemokine 
eotaxin mRNA in the murine lung [Fort et al, 2001; Hurst 2002], resulting in Th2-like 
response and the development of pathological changes including eosinophilic 
infiltrates, epithelial cell hyperplasia/hypertrophy, increased mucus secretion and 
airway hyperreactivity in mice [Fort et al, 2001; Hurst et al, 2002]. 
In the present study, blood samples for Th cell purification were recruited from 
atopic subjects who are sensitive to one or more allergens including food mix, house 
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dust mite, cat, dog, cockroach and mould mix. We speculated that atopic Th cells may 
release a discrete profile of cytokines and chemokines upon costimulation plus IL-18 
or IL-25 when compared with Th cells from healthy volunteers. However, the same 
inductive effects of IL-18 and IL-25 are observed in both groups, despite fluctuations 
in the magnitude of cytokine concentrations due to biological variations. The 
explanation may be that since both the normal and atopic Th cells were extracted and 
cultured in vitro under the same condition, it is possible that they produced the same 
responses. 
To summarize for this part, our study has confirmed that Th cells can take up 
diverse biological actions exhibited by the release of Thl/2 cytokines and chemokines. 
IFN-y and TNF-a, IL-5, IL-6 and IL-8 are cytokines for the activation of 
macrophages, B cells, eosinophils and neutrophils and the induced chemokines can 
also play crucial multiple roles for the accumulation and chemotaxis of various 
leukocytes including eosinophils and neutrophils at the inflammatory sites in the 
bronchial airway [Wong and Lam 2003; Bettiol et al, 2000; Magnan et al, 1999; Lun 
et al, 2006]. Therefore, the above IL-18/25-induced Thl/2 cytokines and chemokines 
can induce severe airway inflammation during allergic asthma. 
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4.2 Regulation of Thl/2 cytokines and chemokines through intracellular p38 
MAPK, ERK, JNK and NF- /c B 
Intracellular signal transduction is a highly interactive network composed of 
various types of protein kinases and other messenger cascades [Dong et al, 2002; 
Wong et al, 2004]. Its complexity allows the fine tune control and integration of the 
signal transduction that can elicit the precise and diversified cellular responses upon 
different extracellular stimulations [Pouyssegur et al, 2002]. As we had demonstrated 
that IL-18 and IL-25 could markedly induce the release of cytokines and chemokines 
from costimulated Th cells, we then focused on the effect of IL-18 and IL-25 on the 
activation of p38 MAPK, ERK, JNK and NK-KB signaling pathways to elucidate their 
intracellular mechanism. 
These pathways have been shown to regulate inflammatory responses [Wong et 
al, 2004]. Endotoxic lipopolysaccharide and proinflammatory cytokines cause marked 
activation of p38 MAPK [Raingeaud et al, 1995]. Report also revealed that activity of 
ERK is significantly higher in asthmatic mice than controls and administration of 
ERK inhibitor can dramatically inhibited eosinophilia, airway mucus production, and 
expression of VCAM-1 in lung tissues in the asthmatic mice model [Duan et al, 2004]. 
In addition, JNK pathway has been shown to be involved in the iip-regulation of 
COX-2 which is highly expressed in inflammation in murine J774 macrophages 
activated by bacterial lipopolysaccharide (LPS) [Nieminen et al, 2006]. Previous 
result from our group showed that the release of chemokines IL-8, IP-10 and MCP-1 
was up-regulated through the activation of NK-KB pathways in bronchial epithelial 
cells co-culturing with eosinophils [Wong et al, 2005]. 
In the present study, costimulation with or without the treatment of IL-18 and 
IL-25 could activate Th cells by rapidly inducing the phosphorylation of ERK, p38 
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M A P K and J N K within 3 0 min. The same treatment could also induce NF-KB activity. 
However, IL-18 and IL-25 alone could not exert any effect on ERK, p38 MAPK, JNK 
and N F - K B activities from resting Th cells without costimulation since resting Th 
cells did not express any IL-18 and IL-25 receptors. 
In an attempt to elucidate the intracellular mechanisms regulating the induction 
of cytokines and chemokines, we used inhibitors BAY 11-7082, PD98059, SP600125 
and SB203580 to elucidate the intracellular signaling mechanisms regulating the 
induction of cytokines. Following our previous studies [Wong et al, 2003, 2005] and 
the toxicity results in Figure 3.8，we used the optimal concentrations of BAY 11-7082 
(1 fiM), PD98059 (5 juM), SP600125 (2.5 |.iM) and SB203580 (5 jaM) with the 
highest inhibitory effect without any cell toxicity. 
We found that in costimulated Th cells, IL-18-induced IFN-y, TNF-a, IL-5, IL-6 
and IL-10, and IL-25-induced IL-5 and IL-10 were mediated by the activation of p38 
MAPK, ERK and N F - K B but not JNK, while IL-25-induced IL-6 was mediated by 
ERK and N F - K B only. Regarding chemokine release, IL-18 and IL-25-induced release 
of IP-10, MIG and RANTES were mediated by JNK only, while IL-18 induced 
M l P - I a and IL-8 were mediated by NF-KB, and both ERK and p38 MAPK, 
respectively. Therefore, the regulation of chemokine release from costimulated Th 
cells upon IL-18 and IL-25 activation was mainly through JNK pathway. We also 
provided evidence that the IL-18/25-induced Thl/2 cytokine release from human Th 
cells were mediated through p38 MAPK, ERK and NF-KB pathways. Our results 
underline the important role of IL-18 and IL-25 in Th cells, as well as in the overall 
allergic reaction. Table 4.1 summarizes the intracellular signaling pathways regulating 
the IL-18/25-induced Thl/2 cytokines and chemokines. 
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Table 4.1 Intracellular signaling pathways regulating the IL-18/25-induced Thl/2 
cytokines and chemokines. 
Thl/2 cytokines IL-18-induced IL-25-induced 
/ Chemokines 
IFN-y p38 M A P K , ERK, NF-KB Not determined 
TNF-a p38 MAPK, ERK, NF-KB Not determined 
IL-5 p38 MAPK, ERK, NF-KB p38 MAPK, ERK, NF-KB 
IL-6 p38MAPK, ERK, NF-KB ERK, NF-KB 
IL-10 p38 MAPK, ERK, NF-KB p38 MAPK, ERK, NF-KB 
IP-10 JNK JNK 
MIG JNK JNK 
RANTES JNK JNK 
MLP-LA NF-KB Not determined 
IL-8 ERK, p38 MAPK Not determined 
Together, the above results therefore imply that the up-regulation of IL-18 and 
IL-25 receptors upon costimulation was the underlying mechanisms for the 
IL-18/25-induced release of cytokines and chemokines from costimulated Th cells. In 
fact, it has been shown that CD28-CD86 costimulation pathway plays a critical role in 
both the induction and effector phase of T cell mediated allergic airway inflammation 
[Van Neerven, et al, 1998; Kimzey et al, 2004]. Moreover, the induction of IL-18 
receptor and IL-18 responsiveness by IL-12 represents a mechanism accounting for 
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the induced IFN-y production by resting T cells [Tomiira et al, 1998]. In our study, 
costimulation-induced IL-18 receptor but not IL-25 receptor was found to be 
mediated by the activation of ERK, p38 MAPK and NF-KB, therefore, IL-18-induced 
cytokines and chemokines were mainly regulated by costimulation activated MAPKs 
and N F - K B and the subsequent up-regulation of IL-18 receptor. However, 
IL-25-induced cytokines and chemokines were regulated by costimulation-mediated 
up-regulation of IL-25 receptor and the IL-25 activated intracellular MAPKs and 
NF-KB. Whether other signaling molecules such as phosphoinositide 3 (PI3)-kinase 
and Th differentiation transcription factors including T-bet, STAT are involved in 
IL-18/25 activation in costimulated Th cells requires further investigation [Okamoto 
eta丨，2003;AgnelIoetal, 2003]. 
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4.3 Effects of costimulation on cell surface markers on Th cells 
To further explore the effects of costimulation on Th cells, we analyzed the cell 
surface expression of adhesion molecules like LFA-1 and ICAM-1, cytokine and 
chemokine receptors such as IL-2R, CCR5, CXCR3, and also costimulatory 
molecules including ICOS and CTLA-4. 
The adhesive interactions between Th cells with vascular endothelium are 
essential for their recruitment to sites of inflammation. Previous in vitro studies have 
demonstrated that T cell adhesion to cultured endothelial cells is mediated by multiple 
adhesion molecules on Th cell surface, including very late antigen (VLA)-4, 
CD49d/CD29), LFA-1 (CD 11 a/CD 18) and P-selectin [Shimizu et al, 1991; 
Luscinskas et al, 1995]. In particular, it has been reported that LFA-1/ICAM-1 
interactions during transendothelial migration enhance the survival of activated T 
lymphocytes at sites of inflammation [Borthwick et al, 2003]. Our results 
demonstrated that resting Th cells express high levels of LFA-1, which could be 
upregulated by costimulation but not further enhanced by IL-18 and IL-25. Therefore, 
up-regLilation of LFA-1 expression on Th cells might promote inflammatory responses 
in allergic inflammation. Unlike LFA-1, ICAM-1 was rarely expressed on the surface 
of resting Th cells, but it was highly upregulated upon costimulation. However, the 
significance of the high expression level remains unclear. Previous study has shown 
that pretreating T cells with anti-ICAM-1 monoclonal antibody inhibits their response 
to recall antigens [Buckle and Hogg, 1990]. Recently, ICAM-1 has also been reported 
to act as co-stimulatory ligand that binds to LFA-1 [Lebedeva et al, 2005]. Therefore, 
ICAM-1 might be important in Th cell activation, whether ICAM-1 expressed by Th 
cells is involved in allergic inflammation requires further investigations. 
Regarding cytokine and chemokine receptors, we demonstrated that 
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costimulation could upregulate cell surface 1L-2R and CXCR3 but not CCR5 
expression on Th cells, which could not be further enhanced by IL-18 and IL-25. 
Since IL-2 is a growth factor for T cells, upregulation of IL-2R upon costimulation 
could further promote cell differentiation and proliferation through positive feedback 
mechanism. CCR5 and CXCR3 are Thl-related chemokine receptors involved in the 
recruitment of 丁 cells to inflammatory sites in response to their corresponding 
chemokines, such as IP-10, MIG, MIP-1, RANTES and I-TAC [Loetscher et al, 1998]. 
It has been reported that CXCR3 expression on Th cells can be upregulated markedly 
following IL-12 stimulation [Loetscher et al, 1998]. Our results showed that CXCR3 
was upregulated upon costimulation. Although CCR5 expression was unchanged, 
IL-12 has been reported to upregulate its expression on T cells upon costimulation 
[Yang et al, 2000]. The upregulation of chemokine receptors might be responsible for 
leukocyte trafficking during inflammatory responses [Adams and Lloyd, 1997]. 
Moreover, further studies are required to assess the expression of Th2-related CCR3 
and CCR4. 
Finally, the expression of costimulatory molecules including ICOS and CTLA-4 
was studied. These molecules can direct, modulate and fine-tune TCR signals [Chen 
et al, 2006]. ICOS binds to B7 family member, B7RP-1 or B7h, on B cells and 
macrophages [Yoshinaga et al, 1999; swallow et al, 1999]. Our results demonstrated a 
95-fold and 12-fold upregulation of ICOS and CTLA-4 respectively upon 
costimulation, which cannot be further enhanced by IL-18 and IL-25. ICOS is a 
positive T cell costimulator which can enhance the proliferation and secretion of 
cytokines [Grimbacher et al, 2003]. The ICOS-mediated signaling contributes to the 
inflammatory response not only through the regulation of IL-4 but also the 
upregulation of the chemokine receptors CCR3, CCR4 and CCR8 [Chen and Shi, 
2006]. On the other hand, CTLA-4, along with its homologue, CD28, is a B7-binding 
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protein [Linsley et al, 1991]. CTLA-4 has a greater binding affinity for B7 molecules 
than CD28 and delivers inhibitory signals for T cell activation [Walunas et al, 1994]. 
A study showed that mice deficient in CD28 have defective Th2 cell development and 
failed to develop inflammation after sensitization and inhaled challenge with 
ovalbumin. However, blockade of B7-CTLA4 interactions in CD28-deficient mice 
restored lymphocyte recruitment to the airway [Burr et al, 2001]. This implicates that 
T-cell recruitment to the airway is mediated through the CTLA4 receptors. Taken 
together, a fine balance between ICOS and CTLA-4 expression was important. High 
ICOS and low CTLA-4 expression may facilitate their optimal Th2 activation and 
recruitment during allergic inflammation. 
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4.4 Concluding remarks and future perspectives 
Although Th2 cells are often found in the lungs of asthmatic patients, 
concomitant presence of Thl cells has also been reported [Bodey et al, 1999]. 
Bronchial asthma could be triggered by viral or bacterial airway infections upon the 
stimulation of toll like receptor (TLR) on epithelial cells to produce IL-18 for Thl 
response [Wardlaw et al, 2002; Seki et al, 2002]. Our previous study has also 
demonstrated the pathological mechanisms for the activation of eosinophils by IL-25 
[Wong et al, 2005]. Our present study showed that IL-18 plus IL-25 and CD28 
costimulation can play pathological roles by worsening airway inflammation and 
hyperresponsiveness by production of both Thl and Th2 cytokines, and chemokines 
upon airway infection. In view of recent advances in the application of MAPK and 
N F - K B inhibitors as potential anti-inflammatory agents in asthma [Duan et al, 2004, 
2005, 2005; Markarov, 2000; Chialda et al, 2005], our study of differential 
mechanisms on the activation of Th cells should provide new insights on the 
development of therapeutic intervention for inflammatory diseases, particularly in 
severe asthma that usually contains both the activation of Thl and Th2 cells, and the 
elevation of chemokines in the local inflammatory sites in lungs. 
In future, we can further characterize the functions of Th cells in inflammation 
by using novel cytokines IL-31 and IL-17F as stimulators. It has been reported that 
IL-31 is associated with human skin-homing cutaneous lymphocyte antigen-positive T 
cells and might contribute to the development of atopic dermatitis-induced skin 
inflammation and pruritus [Bilsborough et al, 2006]. On the other hand, IL-17F has 
been reported in a murine model to induce neutrophilia in the lungs and in the 
exacerbation of antigen-induced pulmonary inflammation [Oda et al, 2005]. With our 
well-established flow cytometric bead-based method, the cytokines and chemokines 
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released from IL-31 and IL-17F activated Th cells and the underlying signaling 
mechanisms can easily be elucidated. In addition, we can further investigate ICOS 
costimulation by using anti-ICOS antibody because we have demonstrated its 
upregulation on Th cells upon costimulation. Gonzalo et al have reported that CD28 is 
critical for priming of Th cells while ICOS plays the predominant role in regulating 
Th2 effector cell activation during inflaininatory responses [Gonzalo et al, 2001]. 
Therefore, ICOS signaling may provide new perspectives in inflammatory diseases. 
The present study investigated the intracellular signaling pathways of p38 
M A P K , J N K E R K and NF-KB . We have shown that IL-18/25-induced THL/2 
cytokines were regulated by intracellular p38 MAPK, ERK and NF-KB, while 
chemokines were mediated mainly through JNK. Other signaling molecules such as 
PI3-kinase and Th differentiation transcription factors including T-bet, STAT may be 
involved in IL-18/25 activation. Evidence showed that these signaling molecules are 
crucial in allergic inflammation. Inhibition of PI3K signaling pathway can suppress 
Th2 cytokine production, eosinophil infiltration, mucus production, and airway 
hyperresponsiveness in a mouse asthma model [Duan et al, 2005]. Besides, it has been 
reported that T-bet is required for the expression of the chemokine receptor CXCR3, 
thus controlling Thl-cell migration to inflammatory sites [Lord et al, 2005], while 
STAT-6 activation leads to Th2-cell migration, chemokine production, airway 
eosinophilia, mucus production and hyperresponsiveness [Matthew et al, 2001]. 
Therefore, further investigation of the above signaling molecules can provide better 
understanding on the role of IL-18 and IL-25 in allergic inflammation. 
As mentioned in 4.1, blood samples in the current study were obtained from 
atopic subjects. However, it was found that Th cells purified from both atopic and 
healthy subjects exhibited the same pattern in the profile of Thl/2 cytokines and 
chemokines. Therefore, it is necessary to find out whether Th cells of allergic patients 
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will differ in their immune responses. In view of the growing interests in the research 
of allergic and infectious diseases, in vitro experiments using purified Th cells from 
patients should closely mimic the physiological condition. 
Lastly, we have elucidated the intracellular signaling mechanism of IL-18/25 on 
costimulated Th cells. However, other T cell subsets, such as regulatory T cells and 
CTL, may also be central in inflammatory and autoimmune diseases. In recent years, 
researches on regulatory T cells have been accumulating rapidly for their roles in 
controlling autoimmunity and maintaining peripheral tolerance. Three subsets have 
been identified so tar including CD4+CD25+ regulatory T cells, Th3 regulatory cells, 
and T-regulatory cell 1 (Trl cells). In particular, Trl cells have been shown to 
possess potent immunosuppressive properties to prevent the development of 
Thl-mediated autoimmune diseases [Groux et al, 1997; Cong et al，2002; McGuirk et 
al, 2002] and Th2 responses [Cottrez et al, 2000] via a mechanism that is partially 
dependent on the production of the iinmunoregulatory cytokines IL-10 and TGF-p. 
Trl cells can be induced in vitro by culturing with anti-CD3 antibodies and the 
complement regulator anti-CD46 in the presence of IL-2 [Kemper et al, 2003]. 
Therefore, the potent immunosuppressive properties by Trl cells make them a good 
target for investigating the activation by cytokines and the underlying signaling 
mechanisms. 
Over the years, CD8+ CTLs have been widely studied in the field of tumor 
immunology. In fact, they are also involved in eliciting allergic and autoimmune 
responses. Unlike Th cells, CTLs become activated upon encountering antigen 
presented by MHC class I complexes on the surface of professional APCs such as 
DCs. CTLs may kill target cells by at least three distinct pathways including (i) 
indirect killing of target cells by releasing TNF-a and IFN-y; (ii) induction of 
apoptosis in target cells; and (iii) direct killing by releasing granzyme B and perforin 
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into the intercellular space. It has been reported that the recruitment of CTLs is 
responsible to induce inflammatory signals and apoptosis of epidermal cells, leading 
to the development of DTH responses, such as allergic contact dermatitis [Girolomoni 
et al, 2004]. Besides, a number of evidence supports the central role of CTLs in 
autoimmune diseases. CTLs have been shown to selectively destroy melanocytes, 
leading to the loss of skin pigmentation in vitiligo, a common hypopigmentary 
disorder [Pedersen et al, 2002; Steitz et al, 2004]. CTLs are also responsible for 
generating other autoimmune diseases, such as type 1 diabetes mellitus and multiple 
sclerosis [Neumann et al, 2002]. Like Th cells, CD8+ CTLs can be purified from 
peripheral blood using magnetic labeling followed by column extraction as 
demonstrated in our study. We have already investigated the role of Th cells in 
allergic inflammation. Further investigation of CTLs should provide new insight in 
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